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INTRODUCTION 
 
1. BREAST CANCER 
1.1 . FEATURES 
Breast cancer (BC) is the most frequent carcinoma in females and the second most 
common cause of cancer-related mortality in women, after lung cancer. According to 
the American Cancer Society, it is expected that the 3 most commonly diagnosed 
types of cancer among women in 2010 will be cancers of the breast, lung and 
bronchus, and colorectum, accounting for 52% of estimated cancer cases in women. 
Breast cancer alone is expected to account for 28% (207,090) of all new cancer cases 
among women, more than 1 in 4 women (Figure 1) (Jemal et al., 2010). 
 
Figure 1: Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths by Sex, 
2010. *Excludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. 
Estimates are rounded to the nearest 10. 
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The decrease in breast cancer incidence, and in particular mortality, has been 
attributed to the combination of early detection with screening programmes, breast 
cancer prevention interventions, a decrease in the use of post-menopausal hormone-
replacement therapy and the advent of more efficacious adjuvant systemic therapy 
(Jemal et al., 2007). Continued advances in our understanding of the molecular 
biology of breast cancer progression have aided in the discovery of novel pathway-
specific targeted therapeutics, and the emergence of such effective therapeutics is 
currently driving the „patient-tailored‟ treatment planning. Knowledge gained from 
studying the molecular pathology of human breast cancer progression, integration 
and implementation of this knowledge in the clinical setting, promises to further 
reduce breast cancer morbidity and mortality. 
 
1.2. EPIDEMIOLOGY AND RISK FACTORS 
The cause of breast cancer is still relatively unknown, although researchers have 
accumulated a considerable amount of information on the factors, which may 
increase one's risk of developing the disease. Today, the disease, like all other forms 
of cancer, is considered to be the end result of many factors, both environmental and 
hereditary. These factors include gender, age, family history of the disease especially 
if there are first degree relatives affected, age at menarche and at menopause, number 
of full term pregnancies, the use of both oral contraceptives and hormone therapies 
and mutation in specific genes. Also the industrialization accompanied by 
environmental pollutants may contribute to breast cancer risk.  
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1.2.1. Gender 
Breast cancer is predominantly a disease that occurs in women even if, in rare 
circumstances, it can develop in men. In fact, approximately one out of every 150 
breast cancer cases occurs in male. It seems likely that estrogens have some role in 
the development of breast cancer; in fact the difference in incidence may be because 
estradiol is able to exert a direct biological effect on breast cells in females, whereas 
in males testosterone needs to be converted to estradiol before exerting any biologic 
effect (Endogenous Hormones and Breast Cancer Collaborative Group, 2002). 
 
1.2.2. Age 
The incidence of breast cancer, in the reproductive years, increases rapidly with age 
then increases at a slower rate after about the age of 50, which is average age at 
menopause (Figure 2).  
 
Figure 2. Age-incidence curve of breast cancer; log-log plot (from data for England and Wales 
1983–87). 
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Younger women are not generally considered to be at risk for breast cancer: only 7% 
of all breast cancer cases occur in women under 40 years old, even if these women 
tend to have more aggressive breast cancers than older women, which may explain 
why often survival rates are lower among younger women. The incidence rates 
increased up to 10-fold by the age of 40 (Hulka and Moorman, 2001). 
 
1.2.3. Effects of migration and geographical factors 
Among populations around the world the incidence and the mortality of breast cancer 
vary greatly, also five-fold (Figure 3). In most of more developed countries the rates 
are high while in less developed countries and in Japan they are low, probably 
because of differences in reproductive factors. Among the migrants, the rates of 
those who migrate from countries with low incidence to countries with high 
incidence take on the higher rates of the new host country (Buell, 1973). 
 
                     
Figure 3. Worldwide variation in breast cancer rates (data from International Agency for Research 
on Cancer 1990). 
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1.2.4. Reproductive factors 
Menarche and the menstrual cycle 
At menarche a woman's body undergoes changes in order to accommodate the 
monthly cycling of sex steroid hormones and to prepare the body for childbearing. 
The age at menarche is inversely related to the risk for development of breast cancer 
(women who begin menstruating before age 13 years, have a two-fold increased risk 
of cancer). Some researchers have suggested that certain characteristics of the 
menstrual cycle, such as the time it takes for regular menstrual cycles, the length of 
menstrual cycles and the age at which these cycles begin, may increase the likelihood 
of developing breast cancer (Butler et al., 2000): for example, a short menstrual cycle 
of less than 28 days confers a greater risk of breast cancer than longer cycles of 28 
days (Whelan et al., 1994). This is because women who have short menstrual cycles, 
would have more cycles throughout a year, and have more time spent in the luteal 
phase of the menstrual cycle and therefore an increase in time spent on cell 
proliferation. Moreover, if fertilization does not occur, there could also be effects on 
apoptosis that would occur more frequently determining a major cancer risk.  
Pregnancy, breastfeeding and abort 
Pregnancy and related factors, such as the age at first full term pregnancy, the 
number of full term births, interruptions in pregnancy (such as abortions) and 
breastfeeding have opposite influences on the risk of developing breast cancer.  
Childbearing seems to have a dual effect on risk of breast cancer: it is increased in 
the period immediately after a birth, but this excess risk gradually diminishes and, in 
the longer term, the effect of a birth is to protect against the disease (Beral and 
Reeves, 1993). Compared with women who never had children (nulliparous women), 
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women who have had at least one full-term pregnancy have, on average, around a 
25% reduction in breast-cancer risk. (Layde et al., 1989). The age at first full term 
pregnancy is related to breast cancer risk. The reason is that the pregnancy induces 
changes in the hormonal profile and these changes could result in alterations in the 
tissues that are under hormonal control. This renders the breast tissue less susceptible 
to carcinogenic stimuli and thus protects from cancer induction (Lambe et al., 1994). 
Furthermore, the protection rises with increasing of full-pregnancies number (Layde 
et al., 1989). 
About the effect of breastfeeding, recent studies in less developed countries, in which 
the total duration of breastfeeding can be much longer, have reported substantial 
protective effects (women who had breastfed for a total of 25 months had a 33% 
lower risk of breast cancer than those who had never breastfed) (Layde et al., 1898). 
Regarding the incomplete pregnancies, arising from spontaneous or induced 
abortions, the risk of breast cancer may be increased because the birth does not go to 
term, and would no longer have a protective effect. During pregnancy there is the 
interplay between prolactin, estrogen and progesterone which all act to promote 
breast growth and differentiation. If the pregnancy is interrupted, the growth and 
differentiation would also be incomplete and the undifferentiated structures of breast 
would render the breast susceptible to carcinogenesis (Russo and Russo, 1980). 
Menopause 
In the breast of postmenopausal women the cellular proliferation tends to be less than 
that of premenopausal women and this reduction of proliferation rate may be due to 
the decline of plasma estrogen concentrations during the menstrual cycle. The age at 
which menopause occurs influences breast cancer risk: women going through 
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menopause at a late age have a higher risk of breast cancer than those who cease 
menstruating earlier (Collaborative Group on Hormonal Factors in Breast Cancer, 
1997). 
A combination of early age at menarche and a late age at menopause would therefore 
prolong the time of the menstrual cycling of sex hormones, and thus would 
substantially increase a woman's risk of breast cancer development (Rosner et al., 
1994). 
 
1.2.5. Hormone therapies  
Hormone therapies are used throughout a woman's reproductive life and decline of 
reproductive years, to combat a variety of ailments. They include oral contraceptives 
and hormones for menopausal women. 
Oral contraceptives 
The use of combined oral contraceptives increases the risk of breast cancer of around 
25%, and the risk falls after cessation of use (10 or more years after use stops, no 
significant increase in risk is evident); risk does not vary significantly with duration 
of use, with the effect of combined oral contraceptives or with the type of estrogen or 
progestagen used. Women with several years of oral contraceptive use before age 25 
and/or before the first full-term pregnancy, women who use oral contraceptives at 
age 45 or older, women with early menarche and women with a family history of 
breast cancer have an increased risk of breast cancer (Vessey et al., 1989). 
Hormonal therapy for the menopause 
Hormone replacement therapies (HRTs) are routinely prescribed for menopausal 
women to alleviate the symptoms of menopause and to slow the bone loss which is 
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associated with postmenopausal osteoporosis. Their use determines a higher risk of 
breast cancer than that of women who have never used these therapies and this risk 
increases with increasing duration of HRT use (Magnusson et al., 1999). 
 
1.2.6. Breast tissue composition 
Breast density reflects variations in breast tissue composition and can be strongly 
associated with breast cancer risk. Breast density is assessed by mammography and 
expressed as the percentage of the breast that is occupied by radiologically dense 
tissue. Researchers found that a major extension of mammographic density percent 
was associated with an increased risk of breast cancer (McCormack and dos Santos 
Silva, 2006). For many women, breast density will change with age or be related to 
factors such as relative body mass index, age at first childbirth, postmenopausal 
hormone replacement use and/or genetic make-up. 
 
1.2.7. Alcohol and smoking 
Observational studies have repeatedly shown that alcohol consumption is associated 
with only a moderate increase in the risk of breast cancer, although it depends on the 
amount and on the type of alcohol taken (Rohan and Bain, 1987). It has been 
suggested that alcohol may induce changes in the liver, which in turn may affect 
estrogen metabolism or may affect the level of steroid binding globulins, or for the 
increased secretion of pituitary stimulated hormones, such as prolactin and thyroid 
stimulating hormone, which would increase mitotic activity in target tissues, and 
hence lead to an increased susceptibility to malignancy. Another hypothesis is that 
the consumption of alcohol (approximately one to two alcoholic drinks per day) 
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increased estrogen levels in premenopausal and postmenopausal women (Ginsburg et 
al., 1959). 
Carcinogens found in tobacco smoke pass through the alveolar membrane and into 
the blood stream, by means of which they may be transported to the breast via 
plasma lipoproteins. Due to the fact that they are lipophilic, tobacco-related 
carcinogens can be stored in breast adipose tissue and then metabolized and activated 
by human mammary epithelial cells (MacNicoll et al., 1980). As is well known, 
tobacco smoke contains potential human breast carcinogens (including PAHs, 
aromatic amines, and N-nitrosamines); in fact an higher prevalence of smoking-
specific DNA adducts and p53 gene mutations were found in the breast tissue of 
smokers compared with that in nonsmokers, supporting the biological plausibility of 
a positive association between cigarette smoking and breast cancer risk, depending 
by dose and duration (Palmer and Rosenberg, 1993). 
 
1.2.8. Diet 
Foods may have several effects on the breast cancer risk. It has been demonstrated 
that aliments rich in omega-3 fatty acids, such as fish, suppress mammary tumour 
growth by blocking the tumour promoting properties of carcinogens or by inhibiting 
prostaglandin synthesis. Conversely, foods rich in omega-6 fatty acids, such as oil, 
are thought to stimulate mammary tumour growth. Both saturated and unsaturated 
fats are thought to act during the promotional stages of carcinogenesis and this 
promotion is largely dependent on the amounts and sources of fat in the diet.  
A link between red meat consumption and risk for breast cancer have been reported 
(Toniolo et al., 1994) while an inverse associations between intakes of fruits, dietary 
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fibre, vegetables and breast cancer risk have been reported in several case-control 
studies because they are important sources of antioxidants, which may help protect 
against the tissue damage linked to increased cancer risk (Fund WCRL, 1997). 
Antioxidants include vitamin C, vitamin E, and Vitamin A such as carotenoids. 
Regarding to caffeine, in a prospective studies, it has not been seen correlation 
between caffeine intake and breast cancer risk (Vatten et al., 1990). 
 
1.2.9. Height, weight and exercise 
Adult height shows a positive association with breast cancer risk. Average height is 
substantially greater in populations with high rates of breast cancer than in 
populations with low rates. Within populations, a 10 cm greater height is typically 
associated with an increase in risk of about 10%. (Hunter and Willett, 1993). 
Probably because height is positively correlated with energy during growth and with 
early menarche, and it might be a marker for the number of susceptible breast cells. 
In postmenopausal women, obesity increases the risk of breast cancer; risk is about 
50% higher in obese women (body-mass index >30 kg/m
2
) than in lean women (body 
mass index 20 kg/m
2
) and this association is not observed in premenopausal women 
(Hunter and Willett, 1993). Several studies have reported that moderate physical 
activity is associated with a lower risk of breast cancer. The size of the effect of high 
physical activity has varied widely between studies, but a typical result is a reduction 
in risk of around 30% in association with a few hours per week of vigorous activity 
versus none (Friedenreich et al., 1998) and more evident in premenopausal women. 
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1.2.10. Family history and genetic factors 
Environmental and lifestyle factors rather than inherited genetic factors account for 
most cases of breast cancer, even if most women with the disease do not have a 
family history of it, and most women with affected relatives never develop breast 
cancer. 
Family history 
The evidence for genetic predisposition to breast cancer derives originally from 
observations of cancer clustering in families and cancer risk increasing in individuals 
with some genetically determined syndromes.  
Most studies on familial risk of breast cancer have found about two-fold relative 
risks for first-degree relatives (mothers, sisters, daughters) of affected patients 
(Pharoah et al., 1997). About 13% of all patients have a first-degree relative with 
breast cancer. A significant increased in breast cancer risk has been observed even in 
second (grandmothers, aunts, grand-daughters) to fifth degree (Amundadottir et al., 
2004). 
High-risk mutations 
About 5-10% of all breast cancers are caused by germ-line mutations in well-
identified breast cancer susceptibility genes (inherited from one‟s mother or father). 
So far at least five germ line mutations that predispose to breast cancer have been 
identified. These include mutations in the genes BRCA1, BRCA2, TP53, PTEN, and 
ATM. Mutations in BRCA1 and BRCA2 can cause high risks of breast cancer because 
they are tumor suppressor genes and their inactivation causes genetic defects and 
genetic instability. Germ line mutations in TP53 predispose to the Li-Fraumeni 
cancer syndrome (including childhood sarcomas and brain tumors, as well as early-
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onset breast cancer) and those in PTEN are responsible for Cowden disease (of which 
breast cancer is a major feature). High-risk alleles probably account for most of the 
families with four or more breast cancer cases, for around 20–25% of the familial 
breast cancer risk overall, and for around 5% of all breast cancers (Easton, 1999). 
The ATM (ataxia telangiectasia mutate) gene control cell cycle and mutations of this 
gene are closely linked to a childhood disorder of the nervous system called Ataxia 
Telangiectasia and to breast cancer susceptibility. 
 
1.3. DISEASE ONSET AND PROGRESSION 
Breast cancer is a group of related conditions, characterized by differing microscopic 
appearance and biologic behavior, in which the cells of the breast escape the normal 
replication, growing and dividing rapidly and uncontrollably (Coe and Steadman, 
1995). It is believed that this capacity of evade from the replication cycle involves 
the accumulation of mutations, usually in genes that regulate cell division and the 
accurate replication of DNA (Davis and Bradlow, 1995). Also hormones and other 
substances located in close proximity of the cell can stimulate abnormal cell 
multiplication. There are many models of human breast cancer evolution. 
Cytogenetic and molecular genetics analysis have revealed that the development of a 
primary breast carcinoma derives from a multistep process involving initiating or 
promoting factors characterized by the accumulation of various genetic alterations 
which may invoke a transformation of normal cells into malignant cells (Beckmann 
et al., 1997) 
One of the most well-established models, published by Wellings and Jensen over 30 
years ago, proposed that the cellular origin of most breast cancers occurs in the 
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normal terminal duct lobular unit (TDLU), the basic histopathologic and 
physiologic unit of breast, and there is an apparently continuous but non-obligatory 
progression from TDLUs to cancers through a series of increasingly abnormal stages 
over long periods of time also decades in most cases (Figure 4) (Wellings and 
Jensen, 1973). 
 
Figure 4. Revised Wellings and Jensen model of human breast cancer evolution. The original 
Wellings and Jensen model proposed an apparently continuous but non-obligatory linear progression 
from normal TDLU to IBC through a series of increasingly abnormal stages over long periods of time. 
 
 The key stages in this progression, in today‟s terminology, are called: 
◊  hyperplastic enlarged lobular units (HELU); 
◊  atypical ductal hyperplasia (ADH); 
◊  ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) so called 
when the tumor remain confined within the basement membrane of the duct or lobule 
(Coe and Steadman, 1995). 
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If the breast cancer remains within the basement membrane and does not invade 
surrounding tissue or metastasize to distant organs it is said to be in situ (non-
invasive) 
◊  invasive breast cancer (IBC) when the tumor increases in size and the invade (or 
infiltrate) the normal adjacent tissue (Allred et al., 2004). When the cancer cells 
break away from the site of origin and penetrate the basement membrane of the 
epithelium, they enter the bloodstream or lymphatics located in connective tissue and 
may metastasize to distant organs and form secondary tumors. The major route of 
metastases via the lymphatic system is through the axillary nodes. Hence, the tumor 
extends into the central lymphatic terminus and the cancer cells enter into the venous 
stream. These cells can then be carried through the heart to lungs. Tumor fragments 
that may break loose from pulmonary vein are then carried off, back to heart and 
enter the bloodstream. Organs with a rich blood supply, such as the liver, spleen, 
adrenals and bone, are the targets for blood-bone metastases (Lu and Kang, 2007). 
. 
Several characteristics distinguish the breast cancer types. The transition from TDLU 
 to HELU is characterized by increased growth due to epithelial hyperplasia. 
Alterations of cell adhesion and polarity distinguish ADH from HELU as the 
hyperplastic epithelium begins to pile up and distends acini. DCIS is characterized by 
further expansion of tumor volume, intraductal spread into other areas of the breast, 
and, most importantly, the appearance of increased histologic and biological 
diversity compared with earlier precursors. Invasion into surrounding stroma defines 
the transition of DCIS to IBC. Evidences support that most high-grade DCIS 
gradually evolve from lower-grade DCIS and, thus indirectly from ADH, by the 
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random accumulation of genetic defects, which are propagated to IBC in a manner 
that is largely independent of progression to invasion. Since the DCIS are the 
precursor of nearly all ductal IBCs (which account for 85-90% of all IBCs), then 
ADH is probably also a risk factor for the development of DCIS independent of its 
histologic and biological characteristics (Allred et al., 2008).  
Since the major breast cancers evolve from precursors, identifying of biological 
alterations associated with early precursors, before the cancer development, may 
reveal strategies for the prevention of the majority of cancers or treated them early. 
 
1.4. CLASSIFICATION AND CLINICAL PATHOLOGY 
When cancer is present, a number of tests are performed to assess the behavior of the 
cancer, and to determine the most effective treatments. 
Prognosis is defined according to several parameters: tumor size and grade, the 
presence/ absence of estrogen (ER) and/or progesterone (PR) receptors, HER2/neu 
(HER2, c-erbB2) protein, lymph node metastases and vascular or perineural tumor 
invasion. Other parameters, such as the proliferating index, the presence of p53, 
BRCA1 and 2 or EGFR alterations, may also be useful for prognostic evaluation or 
as predicting therapeutic response. 
The TNM Classification of Malignant Tumors (TNM) is a cancer staging system for 
all solid tumors that describes the extent of cancer in a patient‟s body. It was devised 
by Pierre Denoix between 1943 and 1952 using the size and extension of the primary 
tumor, its lymphatic involvement, and the presence of metastases to classify the 
progression of cancer. The parameters are: 
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● T (range from 1 to 4) describes the size of the primary tumour and whether it has 
invaded nearby tissue: 
o T1: No evidence of primary tumour  
o T2: Tumor 2 cm or less 
o T3: Tumour more than 5cm 
o T4: Tumour of any size with extension to adjacent tissue 
 
● N (range from 0 to 3) describes regional lymph nodes that are involved and the 
degree of spread: 
o N0: tumor cells absent from regional lymph nodes 
o N1: regional lymph node metastasis present; (at some sites: tumor 
spread to closest or small number of regional lymph nodes) 
o N2: tumor spread to an extent between N1 and N3 (N2 is not used at 
all sites) 
o N3: tumor spread to more distant or numerous regional lymph nodes 
(N3 is not used at all sites); 
● M (0-1) represents the presence of metastasis (spread of cancer from one body 
part to another). 
o M0: no distant metastasis 
o M1: metastasis to distant organs (beyond regional lymph nodes) 
 
1.4.1. Tumour Stage 
Once a TNM classification is available for a tumour, the tumour is then classified 
into a clinical stage; stage I, II, III, or IV (Table 1) (Sainsbury et al., 1994). 
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Table 1. The correlation of the tumour, nodes, metastases (TNM) system and the Unio 
Internationale Contra  Cancrum (UICC) system of classification for tumours. 
 
Survival from breast cancer is largely dependent on the stage at presentation, and the 
prescription of appropriate treatment is based on stage. 
 
1.4.2. Tumour Grade 
On microscopic examination, a tumour can be graded according to the degree of 
differentiation of the tumour from adjacent "normal" cells. The most common 
grading system used by pathologists is the Scarff, Bloom, and Richardson (SBR) 
classification and is usually used as a preference to tumour staging. 
 
Tumour Grade Definition:  
◊ Tumor grade 1: tumor well-differentiated 
◊ Tumor grade 2: tumor moderately-differentiated 
◊ Tumor grade 3: tumor poorly-differentiated 
 
Grade 1 tumors are small, round, have regular nuclei and very few mitoses. 
Conversely, grade 3 tumors are large, have irregular nuclei and have many mitoses  
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Survival studies show that grade 1 tumors have a good prognosis, and thus a good 
response to treatment, whilst grade 3 tumors would have a poor prognosis and the 
response to treatment would be less successful (Elledge and McGufre, 1993). 
 
1.4.3. Tumour size 
The size of the primary tumour and the involvement of axillary nodes (which, 
combined, constitute the stage of the disease) in cancer development, are the most 
important indicators of prognosis. A good prognosis is associated with a small 
tumour (less than 1cm in diameter); whilst a poor prognosis accompanies a large 
tumour (a diameter greater than 5cm) (Stockdale, 19889. Results from the SEER 
program (Surveillance, Epidemiology and End Results program of the National 
Cancer Institute) suggest that if tumors are less than 1cm in diameter and have not 
progressed from the initial site of development, then there is a relatively high chance 
of survival, after 5 years, from the time of primary diagnosis, in comparison, tumors 
of greater than 5 cm in diameter, have an 82% chance of survival after 5 years from 
the initial time of diagnosis (Carter. Et al., 1989). 
 
1.4.4. Estrogen and progesterone receptors 
Hormone receptor assays are considered to be essential tools for the assessment, 
prognosis and treatment of breast cancer. Approximately 50 to 85% of breast cancers 
cells contain receptors that specifically bind estrogen and progesterone.  
Estrogen receptors (ER) and progesterone receptors (PR) are present in higher 
concentrations in breast cancer tissue than in "normal" breast tissue, and are thus 
significantly important for planning treatment. In fact, about 75% of breast cancers 
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are estrogen receptor-positive (ER-positive, or ER+). About 65% of ER-positive 
breast cancers are also progesterone receptor-positive (PR-positive, or PR+). Cells 
that have receptors for one of these hormones, or both of them, are considered 
hormone receptor-positive. Patients with breast cancers that are shown to be ER 
positive, respond favorably to hormone treatments such as tamoxifen, in 
approximately 60-65% of cases. On the contrary, patients with negative ER assays 
have a less than 10% response rate to hormone therapy (Stockdale, 1988). Therefore 
a high concentration of these receptors is highly predictive of the response hormonal 
therapy. 
 
1.4.5. Proliferation index 
The proliferation index is a measure of the number of cells in a tumor that are 
dividing, and thus proliferating. Cell proliferation can reasonably be supposed to be 
related to tumor aggressiveness. Proliferative activity can be determined using 
various methods based on different rationales: 
Ki-67 protein is an indicator strictly associated with cell proliferation. During 
interphase, the Ki-67 antigen can be detected only within the nucleus of cells, while 
in mitosis the majority of the protein is relocated to the surface of chromosomes. The 
Ki-67 protein is present during all active phases of cell cycle (G1, S, G2 and M) but 
it is absent from resting cells (G0). Ki-67 is an excellent indicator to determine the 
fraction of development given population of cells. The fraction of Ki-67 positive 
tumor cells (Ki-67 labeling index) is often correlated with the clinical course of 
cancer. 
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The mitotic index (MI) is the fraction of cells in mitosis at any given time. It 
consists in counting the number of mitotic figure on a constant sample of cells (1000 
or 10000) per mm
2
 of epithelium. Mitotic activity is currently used mainly as part of 
the tumor grading system, for women with infiltrating breast carcinoma. Several 
studies have indicated that mitotic activity is an important imprint of tumor evolution 
as it exerts a determining influence on long-term clinical outcome, regardless of type 
of treatment, but also they suggested that mitotic activity does not provide predictive 
information on response to systemic therapy (Medri et al, 2003). 
The thymidine labeling index (TLI) is a method, which involves the incubation of 
fresh tissue with tritium-labeled thymidine, provides an estimate of the fraction of 
tumor cells that are in the S (DNA synthesis) phase of the cell cycle. Because DNA 
synthesis is an integral part of each cell division cycle, TLI gives an indication of the 
amount of proliferation taking place in a tumor and it is a strong independent 
predictor of survival and relapse-free survival. 
Both Ki-67 and TLI are high in cancers with high nuclear and histologic grade and 
are higher in cancers from premenopausal women than in those from postmenopausal 
women (Gentili et al., 1981; McGurrin et al, 1987); tumors with high TLI or Ki-67 
are frequently estrogen receptor negative (Gerdes et al, 1987). 
 
1.4.6. HER2-neu 
HER2/neu (Human Epidermal growth factor Receptor 2, also known as ErbB-2) is a 
member of the ErbB protein family, more commonly known as the epidermal growth 
factor receptor family, and it is encoded by the ERBB2 gene. It is a cell membrane 
surface-bound receptor tyrosine kinase and is normally involved in the signal 
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transduction pathway leading to cell growth. In breast cancer approximately 30% 
have an amplification of HER2/neu gene or overexpression of its protein product, 
giving higher aggressiveness, increased disease recurrence and worse prognosis of 
breast cancer patients. 
 
1.4.7. p53 
p53 is a tumor suppressor protein that regulates the cell cycle and plays a role in 
genetic stability and inhibition of angiogenesis; it exerts its anti-cancer role through 
several mechanisms (activates DNA repair proteins, induces growth arrest and 
initiates apoptosis). More than 50% of human tumors contain mutations or deletions 
of the TP53 gene. While the prognostic and predictive value of p53 is still matter of 
debate, there is an increased interest for p53-based therapies. 
 
1.4.8. BRCA1 and BRCA2 
BRCA1 and BRCA2 are two tumor suppressor genes with several functions such as 
repair DNA double-strand breaks, protein ubiquitylation and cell cycle checkpoint 
control. Germ line mutations of these two genes confer strong lifetime risks of breast 
cancer and the risks are influenced by the position of mutation within the gene 
sequence (Easton, 1997). Researchers have identified hundreds of mutations in the 
BRCA1 and BRCA2 genes, many of which are associated with an increased risk of 
cancer. Women with a family history of breast cancer are screened for mutations in 
their BRCA1 and BRCA2 genes. 
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1.4.9. EGFR 
The Epidermal Growth Factor Receptor (EGFR) is a cell-surface receptor for 
members of epidermal growth factor family (EGF-family) of extracellular protein 
ligands. The binding by ligands activates EGFR dimerization and stimulates intrinsic 
intracellular protein-tyrosine kinase activity. The downstream signaling proteins 
initiate several signal transduction cascades, principally MAPK, Akt and JNK 
pathways leading to DNA synthesis and cell proliferation. 
The expression of EGFR in models of breast cancer is associated with increased 
proliferation and resistance to apoptosis and with poorer prognosis. Mutations that 
lead to EGFR overexpression or over-activity have been associated with breast 
cancer: it is overespressed in 35-60% of breast cancers.  
 
1.5. TYPES AND SUBTYPES 
The normal female adult breast consists of a mixture of epithelial and stromal 
elements. The epithelial elements of the breast contain a series of branching ducts, 
which extends from the nipple, and terminates into the functional units of the breast, 
the lobules (DiSaia, 1993). Each breast is composed of 15-20 lobules, containing a 
cluster of alveoli, which are responsible for the secretion of milk during lactation. 
The stroma contains variable amounts of interspersed adipose tissue and fibrous 
connective tissue, which constitutes most of the breast volume in a non-lactational 
state (Carola et al., 1992; DiSaia, 1993).  
The two most common types of breast cancer are named after the parts of the breast 
in which they start (Figure 5): 
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Figure 5. Anatomy of breast  
 
● Ductal Carcinoma in situ (DCIS): it is the most common type of non invasive 
breast cancer, in fact between 85% and 90% of all breast cancers are ductal. It starts 
inside the milk ducts, beneath the nipple and areola and it is well contained, hasn‟t 
spread beyond the milk duct into any normal surrounding breast tissue, and it can be 
very successfully treated. The DCIS cancers have a higher risk for recurrence (most 
recurrences happen within the 5 to 10 years after initial diagnosis and the chances of 
a recurrence are under 30%) and for developing a new breast cancer. 
● Lobular Carcinoma: about 8% of breast cancers are lobular. LCIS begins in the 
lobes, or glands which produce milk in the breast and the cancer is limited within the 
lobe and has not spread to surrounding tissues. Despite the fact that its name includes 
the term “carcinoma,” LCIS is not a true breast cancer. Rather, LCIS is an indication 
that a person is at higher-than-average risk for getting breast cancer at some point in 
the future. LCIS is usually diagnosed often between the ages of 40 and 50. 
These two cancer types are usually removed during a lumpectomy if the tumor 
margins are clear of cancer, follow-up treatment may include radiation. If ductal 
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cancer has broken into nearby breast tissue (invasive cancer) then a mastectomy may 
be needed, and also chemotherapy.  
Second most common is a group of breast cancers that invade nearby tissue:  
● Invasive (Infiltrating) Breast Cancer has the potential to spread out of the 
original tumor site and to invade other parts of your breast, the lymph nodes and 
other areas of the body. There are several types and subtypes of invasive breast 
cancer such as invasive ductal carcinoma and invasive lobular carcinoma. The 
treatments fall into two broad categories: local (surgery and radiation) or systemic 
(chemotherapy, hormonal and target therapy). 
Other breast cancer types are: 
● Inflammatory Breast Cancer: is the least common (1-5% of all breast cancer), 
but most aggressive of breast cancers, taking the form of sheets or nests, instead of 
lumps. It can start in the soft tissues of the breast, just under the skin, or it can appear 
in the skin. Unlike ductal and lobular cancers, it is treated first with chemotherapy 
and then with surgery. When caught early, inflammatory breast cancer can be a 
manageable disease, and survival rates are increasing. 
● Paget's disease of the nipple/areola is a rare form of breast cancer, often looks 
like a skin rash, or rough. The itching and scabs are signs that cancer may be under 
the surface of the skin, and is breaking through. The cancer usually affects the ducts 
of the nipple first (small milk-carrying tubes), then spreads to the nipple surface and 
the areola. The disease usually develops after age 50 and is usually treated with a 
mastectomy, because the cancer has by then invaded the nipple, areola, and the milk 
ducts.  
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● Rare types of breast cancer include: 
- Medullary breast cancer (5%) 
- Mucinous (mucoid or colloid) breast cancer (2%) 
- Tubular breast cancer (1%) 
- Adenoid cystic carcinoma of the breast (1%) 
- Metaplastic breast cancer (is a mixture of two cell types; 1%) 
 
Human breast cancer is a heterogeneous disease, encompassing a number of distinct 
biological entities that are associated with specific morphological and 
immunohistochemical features and clinical behavior and, therefore, no golden 
standard therapy exists suitable for all tumors of the mammary gland (Lacroix et al., 
2004). For many decades, breast carcinomas were only classified according to 
histological type, grade, and expression of hormone receptors as described above. 
However, this classification proved to be limiting for it was unable to define 
subgroups sharing similar prognostic and therapeutic aspects. A more recent 
approach to classify breast cancer subgroups is gene expression profiling, based on 
cDNA microarrays (Care et al., 2006; Sorlie et al., 2001), which suggests the 
presence of multiple molecular subtypes of breast cancer. Based on transcriptomic 
similarity, breast carcinomas can be distinguished into five “intrinsic” main distinct 
subtypes: 
- Luminal A (ER positive, and/or PR positive, HER2 negative) 
- Luminal B (ER positive and/or PR positive, HER2 positive) 
- Triple negative (or also basal like) (ER negative, PR negative, HER2 negative) 
- HER2 positive (ER negative, PR negative, HER2 positive) 
- Normal Breast-like 
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Known as the „intrinsic subtypes of breast cancer‟, these groups of tumors have 
revealed critical differences in incidence (Millikan et al., 2008), survival (Cheang et 
al., 2009; Hu et al., 2006), and response to treatment (Prat et al., 2010; Nielsen et al., 
2010). For example, luminal tumors have been associated with the most favorable 
prognoses, while HER2-overespressing and triple-negative have been associated with 
the worst prognoses. 
 
1.5.1 TRIPLE-NEGATIVE BREAST CANCER 
Triple-negative breast cancers (TNBC) account for 10–17% of all breast carcinomas 
(Reis-Filho and Tutt, 2008) are reported to be more commonly seen in younger 
women, often in pre-menopausal women (<50 years), of African-American and 
Hispanic ethnicity (Morris et al., 2007), with BRCA1 mutations (Dent et al., 2007), 
an increased body weight (Trivers et al., 2009). It have been characterized by several 
aggressive clinicopathologic features including higher mean tumor size, higher 
histologic grade tumors, elevated mitotic count, ductal or mixed histology, and, in 
some cases, a higher rate of node positivity (Dent et al., 2007; Irvin and Carey, 
2008). TNBC have a worse prognosis than the other breast cancer subtypes, high 
recurrence, occurring within three years of diagnosis and mortality rates are 
increased for five years after diagnosis, and development of recurrence and distant 
metastasis with a specific metastatic pattern (meninges, brain, liver and lung) (Rakha 
et al., 2007). Due to the absence of hormone receptors and HER2 expression, these 
tumors cannot take advantage from the endocrine therapy or trastuzumab treatment, 
chemotherapy remaining the only potential adjuvant therapeutic approach. As far as 
sensitivity to chemotherapy is concerned, the TNBCs exhibit higher rates of 
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objective response to neoadjuvant chemotherapy than other tumor types (Reis-Filho 
and Tutt, 2008), thus suggesting that biological features present more frequently in 
this group are responsible for the increased sensitivity to chemotherapy. In general, 
adjuvant therapeutic options for TNBC can be divided into two groups: cytotoxic 
agents (as anthracycline agents or platinum-containing agent) and targeted therapies 
(as PARP1 and EGFR or VEGF inhibitors). Although triple-negative cancers are 
report to have excellent response rates to neoadjuvant chemotherapy (Rouzier et al., 
2005), survival of patients with such tumors is still poor and their management may 
therefore require a more aggressive alternative intervention and it remains an urgent 
need to understand the molecular and biological features of these tumors in order to 
develop novel therapeutic strategies to improve their clinical outcome. 
 
1.6. THERAPY 
The mainstay of breast cancer is surgery when the tumor is localized, followed by 
chemotherapy, radiotherapy and hormonal therapy for ER positive tumor, depending 
on clinical criteria. Treatments are given with increasing aggressiveness according to 
the prognosis and risk of recurrence. 
 
1.6.1 Surgery  
Surgery is usually the first line of attack against breast cancer. Some of the lymph 
nodes under the arm are usually taken out and looked at under a microscope to see if 
they contain cancer cells. Several types of surgery exist to remove breast cancer. 
Breast-conserving surgery, an operation to remove only the cancer but not the breast 
itself, includes the following:  
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 Lumpectomy: Surgery to remove a tumour (lump) and a small amount of normal 
tissue around it.  
 Partial mastectomy: Surgery to remove the part of the breast that has cancer and 
some normal tissue around it.  
Other types of surgery include the following: 
  Total mastectomy: Surgery to remove the whole breast that has cancer. Some of 
the lymph nodes under the arm may be removed for biopsy. 
 Modified radical mastectomy: Surgery to remove the whole breast that has 
cancer, many of the lymph nodes under the arm, the lining over the chest 
muscles, and sometimes, part of the chest wall muscles. 
 Radical mastectomy: Surgery to remove the breast that has cancer, chest wall 
muscles under the breast, and all of the lymph nodes under the arm 
 
Radiation therapy  
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of 
radiation (gamma rays). This radiation is very effective in killing cancer cells that 
may remain after surgery or recur where the tumor was removed. 
There are two types of radiation therapy. External radiation therapy uses a machine 
outside the body to send radiation toward the cancer. Internal radiation therapy (or 
brachytherapy) uses a radioactive substance sealed in needles, seeds, wires, or 
catheters that are placed directly into or near the cancer. The way the radiation 
therapy is given depends on the type and stage of the cancer being treated. Although 
radiation therapy can reduce the chance of breast cancer recurrence, it is much less 
effective in prolonging patient survival. According to a review of six studies by the 
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United States' National Cancer Institute, none of them found a survival benefit for 
radiation therapy (Porter et al., 1993). 
 
Chemotherapy  
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer 
cells. The mechanism of action of chemotherapy is to destroy fast growing or fast 
replicating cancer cells either by causing DNA damage upon replication or other 
mechanisms; these drugs also damage fast-growing normal cells where they cause 
serious side effects. Chemotherapy is used to treat: early-stage invasive breast cancer 
to get rid of any cancer cells that may be left behind after surgery and to reduce the 
risk of the cancer coming back; advanced-stage breast cancer to destroy or damage 
the cancer cells as much as possible. In some cases, chemotherapy is given before 
surgery to shrink the cancer. 
When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs 
enter the bloodstream and can reach cancer cells throughout the body (systemic 
chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, 
an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells 
in those areas (regional chemotherapy). The way the chemotherapy is given depends 
on the type and stage of the cancer being treated. Some protocols call for a cycle of 
treatment every three weeks; others may be more frequent. 
It predominately is used for stage 2-4 disease, but may also be used to treat types of 
early-stage breast cancer. Many different types of chemotherapy drugs are used to 
treat this cancer and often they are administered in combination (regimen). 
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 One of the most common treatments is cyclophosphamide plus doxorubicin 
(Adriamycin), known as AC. Sometimes a taxane drug, such as docetaxel, is added, 
and the regime is then known as CAT; taxane attacks the microtubules in cancer 
cells. Another common treatment, which produces equivalent results, is 
cyclophosphamide, methotrexate, and fluorouracil, known as CMF.  
 
Hormone therapy  
Hormones are substances produced by glands in the body and circulated in the 
bloodstream. Some hormones can cause certain cancers to grow. Hormonal therapy 
medicines treat hormone-receptor-positive breast cancers in two ways: by lowering 
the amount of the hormone estrogen in the body or by blocking the action of estrogen 
on breast cancer cells, stopping their growth. 
If tests show that the cancer cells have places where hormones can attach (receptors), 
drugs, surgery, or radiation therapy are used to reduce the production of hormones or 
block them from working. The hormone estrogen, which makes some breast cancers 
grow, is made mainly by the ovaries. Treatment to stop the ovaries from making 
estrogen is called ovarian ablation.  
Hormone therapy with tamoxifen is often given to patients with early stages of breast 
cancer and those with metastatic breast cancer. Hormone therapy with tamoxifen or 
estrogens can act on cells all over the body and may increase the chance of 
developing endometrial cancer. Hormone therapy with an aromatase inhibitor is 
given to some postmenopausal women who have hormone-dependent breast cancer. 
Hormone-dependent breast cancer needs the hormone estrogen to grow. Aromatase 
inhibitors decrease the body's estrogen by blocking an enzyme called aromatase from 
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turning androgen into estrogen. For the treatment of early stage breast cancer, certain 
aromatase inhibitors may be used as adjuvant therapy instead of tamoxifen. 
 
Targeted therapy  
Targeted therapy is a type of treatment that uses drugs or other substances to identify 
and attack specific cancer cells without harming normal cells. Monoclonal antibodies 
and tyrosine kinase inhibitors are two types of targeted therapies used in the 
treatment of breast cancer. 
Monoclonal antibody therapy is a cancer treatment that uses antibodies made in the 
laboratory, from a single type of immune system cell. These antibodies can identify 
substances on cancer cells or normal substances that may help cancer cells grow. The 
antibodies attach to the substances and kill the cancer cells, block their growth, or 
keep them from spreading. Monoclonal antibodies are given by infusion. They may 
be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells 
ant they may be used in combination with chemotherapy as adjuvant therapy. 
Trastuzumab (Herceptin) is a monoclonal antibody that blocks the effects of the 
growth factor protein HER2, which sends growth signals to breast cancer cells. 
About one-fourth of patients with breast cancer have tumors that may be treated with 
trastuzumab combined with chemotherapy.  
Another important monoclonal antibody used for the antiangiogenic therapy is 
Bevacizumab that blocks the VEGF receptor protein, which is involved in forming 
tumor blood vessels.  
Tyrosine kinase inhibitors are targeted therapy drugs that block signals needed for 
tumors to grow. Also tyrosine kinase inhibitors may be used in combination with 
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other anticancer drugs as adjuvant therapy. Lapatinib is a tyrosine kinase inhibitor 
that blocks the effects of the HER2 protein and other proteins inside tumor cells. It 
may be used to treat patients with HER2-positive breast cancer that has progressed 
following treatment with trastuzumab. 
PARP inhibitors are a type of targeted therapy that block DNA repair and may cause 
cancer cells to die. PARP inhibitor therapy is being studied for the treatment of 
triple-negative breast cancer. 
 
Stage 1 cancers (and DCIS) have an excellent prognosis and are generally treated 
with lumpectomy and sometimes radiation. HER2+ cancers should be treated with 
the trastuzumab (Herceptin) regime (Gonzalez-Angulo et al., 2009) chemotherapy is 
uncommon for other types of stage 1 cancers. Stage 2 and 3 cancers with a 
progressively poorer prognosis and greater risk of recurrence are generally treated 
with surgery (lumpectomy or mastectomy with or without lymph node removal), 
chemotherapy (plus trastuzumab for HER2+ cancers) and sometimes radiation 
(particularly following large cancers, multiple positive nodes or lumpectomy). Stage 
4, metastatic cancer, (i.e. spread to distant sites) has poor prognosis and is managed 
by various combination of all treatments from surgery, radiation, chemotherapy and 
targeted therapies. 
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2. CHEMOTHERAPY 
2.1. FEATURES 
Chemotherapy for the treatment of cancer was introduced into the clinic more than 
fifty years ago. Chemotherapy refers to antineoplastic drugs or chemical used to treat 
cancer. Chemotherapeutic drugs acts by killing cells that divide rapidly, one of the 
main properties of most cancer cells. Since malignant cells divide without control or 
order, these drugs effectively target cancerous growths. Ideally, chemotherapeutic 
drugs should specifically target only neoplastic cells and should decrease tumor 
burden by inducing cyto-endotoxic and/or cytostatic effects with minimal “collateral 
damage” to normal cells. Indeed, chemotherapy inadvertently also harms healthy 
cells that divide rapidly under normal circumstances: cells in the bone marrow, 
digestive tract and hair follicles; this results in the most common side effects of 
chemotherapy: myelosuppression (decreased production of blood cells, hence also 
immunosuppression), mucositis (inflammation of the lining of the digestive tract), 
and alopecia (hair loss). 
There are various types of cancer those need different type of drugs that kill cancer 
cell in different ways at various phases in the cell cycle. Depending on the type, size, 
and location of the cancer, as well as your overall health, there are different strategies 
in the administration of chemotherapeutic drugs: 
● Neoadjuvant Chemotherapy: refers to the administration of therapeutic agents 
prior to the main treatment, that usually it is the surgery. The aim is to reduce the size 
or extent of the cancer before employing radical treatment intervention, thus making 
procedures easier and more likely to be successful, and reducing the consequences of 
a more extensive treatments technique. 
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● Adjuvant chemotherapy: refers to additional treatment, usually given after 
primary therapy (surgery or radiotherapy) where all detectable disease has been 
removed, but where there remains a statistical risk of relapse due to occult disease. 
This treatment strategy permit to kill any remaining cancer cells in the body. 
● Palliative chemotherapy: is given to patients who develop metastatic disease 
(cancer that spreads throughout the body) which are generally not curable. New 
advances in drug therapies, however, can help shrink tumors, prolong survival, and 
improve quality of life. Palliative treatments are also used to help relieve cancer-
related symptoms, improving the patient‟s quality of life. 
 
First line chemotherapy is treatment with chemotherapeutic drugs that has, through 
research studies and clinical trials, been determined to have the best probability of 
treating a given cancer. This may also be called “standard therapy”. 
Second line chemotherapy: is chemotherapy that is given if a disease has not 
responded or reoccurred after first line chemotherapy. In some cases, this may also 
be referred to as “salvage therapy”.  
 
Multiple chemotherapeutic agents may be used in combination to treat patients with 
breast cancer. Determining the appropriate regimen to use depends on many factors; 
such as, the character of the tumor, lymph node status, and the age and health of the 
patient. In general, chemotherapy has increasing side effects as the patient's age 
passes. 
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2.2. CHEMOTHERAPEUTIC DRUGS ANS MECHANISM OF     
       ACTION 
Currently there are many drugs, about a hundred, which can be used in cancer 
treatment. The majority of chemotherapeutic drugs can be divided into: 
 
Alkylating agents: are drugs that act directly on DNA, causing cross-linking of 
DNA strands, abnormal base pairing, or DNA strand breaks, thus preventing the cell 
from dividing. Alkylating agents are generally considered to be cell cycle phase non-
specific, meaning that the kill the cell in various and multiple phases of the cell 
cycle. Although alkylating agents may be used for most types of cancer, they are 
generally of greatest value in treating slow-growing cancers. Examples of these 
drugs are: 
- classical alkylating agents, that are drugs with true alkyl groups, which including    
   three subgroups: nitrogen mustards such as cyclophosphamide and melphalan,  
   nitrosoureas such as carmustine, and alkyl sulfonates such as busulfan; 
- alkylating-like agents that are platinum-based drugs, don‟t have an alkyl group but  
   nevertheless damage DNA (Cruet-Hennequart et al., 2008) and including cisplatin,  
   oxaliplatin and carboplatin. 
 
Antimetabolites: are chemical that interfere with the formation or use of a normal 
cellular metabolites, interfering with DNA or RNA production and therefore cell 
division and the tumor growth. Antimetabolites are cell cycle specific, in fact they 
are most effective during S-phase of cell division because they primarily act upon 
cells undergoing synthesis of new DNA for formation of new cells. Indeed 
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antimetabolites masquerade as a purine or a pyrimidine chemicals which become the 
building blocks of DNA and they prevent these substance becoming incorporated in 
to DNA during S phase stopping normal development and division. The toxicities 
associated with these drugs are seen in cells that are growing and dividing quickly. 
Examples of antimetabolites include: 
- purine antagonists (act by mimicking the structure of metabolic purines) such as 6- 
  mercaptopurine; 
- pyrimidine antagonists (act by mimicking the pyrimidine structures) such as 5- 
  fluorouracil, Gemcitabine and Cytarabine; 
- folate antagonists (impair the acid folic function) such as Methotrexate. 
Methotrexate is one of the most commonly used chemotherapy agents and works on 
the S-phase of the cell cycle. It is an analogous of folic acid and acts by inhibiting 
dihydrofolate reductase (DHFR) and, therefore, the metabolism of folic acid required 
for DNA synthesis and also for RNA and proteins. 
5-Fluorouracil (or 5-FU) is a pyrimidine analogous which works through non 
competitive inhibition of thymidylate synthase, blocking the synthesis of the 
thymidine required for DNA replication, inducing cell cycle arrest.   
 
Anti-tumor antibiotics: have several mechanisms of action to block cell growth, by 
interfering with DNA and RNA synthesis, and they work in all phase of the cell 
cycle. Example of anti-tumor antibiotics including: 
- anthracyclines (act by inhibiting DNA and RNA synthesis by intercalating between  
  base pairs of DNA/RNA strand preventing the replication of rapidly-growing  
  cancer cells or by creating iron-mediated free oxygen radicals that damage the DNA  
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and cell membranes) that include doxorubicin; 
- actinomycins (act by binding DNA at the transcription initiation complex  
  preventing the elongation by RNA polymerase) including actinomycin-D; 
- bleomycins (act by inducing DNA strand breaks). 
Doxorubicin (or also Adriamycin) is used to treat wide range of cancer (carcinomas, 
sarcomas and hematological malignancies) and acts with DNA by intercalation 
(Fornari et al., 1994) and by inhibition of macromolecular biosynthesis (Momparler 
et al., 1976). Doxorubicin stabilizes the topoisomerase II complex preventing the 
DNA double helix from being released and thereby stopping the process of 
replication. 
 
Mitotic inhibitors are drugs derived from plants and other natural products that 
block cell division by preventing microtubule functions during mitosis. Microtubules 
are polymers made of tubulin protein. They are created during normal cell functions; 
they move and separate the chromosomes and other components of the cell for 
mitosis. Therefore they are vital for cell division and, without them, cell division 
cannot occur, triggering the apoptosis. These drugs interfere with the assembly and 
disassembly of tubulin into microtubules and act primarily during M-phase of cell 
cycle, but they can also do so in all phases. The main examples are: 
- vinca alkaloids derived from periwinkle plant, vinca rosea (act by binding to  
  specific sites on tubulin inhibiting the assembly of tubulin into microtubules) such  
  as Vincristine; 
- taxanes derived from Pacific yew tree (act by destroying the microtubule function  
  preventing the separation of chromosomes during anaphase) including paclitaxel; 
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- podophyllotoxins extracted from American May Apple tree (prevent the cell from  
  entering the G1 phase and the replication of DNA and is the pharmacological  
  precursor for etoposide agent). 
 
Topoisomerase inhibitors: are agents designed to interfere with the action of 
topoisomerase enzymes (I and II), which are enzymes that control the changes in 
DNA structure, maintaining the topology of DNA and control the integrity of the 
genetic material during transcription, replication and recombination processes during 
the normal cell cycle. Topoisomerase inhibitors interfere with both transcription and 
replication of DNA, by upsetting proper DNA supercoiling, and can be divided 
according to which type of enzyme they inhibit:  
- topoisomerase I inhibitors such as irinotecan, topotecan and camptothecin; 
- topoisomerase II inhibitors including etoposide and mitoxantrone. 
 
Hormone therapy 
Drugs in this category are sex hormones, or hormone-like drugs, that alter the action 
or production of female or male hormones. The concept of this therapy is that the 
cancer cells of an organ sensitive to hormones may be subjected to hormonal control 
and an altered hormonal environment, blocking use of hormones or preventing the 
body from making them, inhibition produces a remission of tumor.  
There are several types of hormonal therapy including: 
- aromatase inhibitors (work blocking the enzyme aromatase which turns the  
  hormone androgen into small amounts of estrogen in the body) such as letrozole;  
- selective estrogen receptors modulators (SERMs) (work by sitting in the estrogen  
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  receptors of cancer cells and so estrogen can‟t attach to the cell and this can‟t grow)  
  such as tamoxifen; 
- estrogen receptor downregulators (ERDs) (enter in the estrogen receptors of cell  
  and so estrogen cannot attach to the cell and the cell can‟t grow but also it reduce  
  the number of estrogen receptors) such as fulvestrant. 
 
Some of the abbreviations used for chemotherapy drug combinations (regimens) 
refer to drug classes rather than drug names. For example, regimens that contain an 
anthracycline drug (such as doxorubicin) use the letter "A," and regimens that 
contain a taxane drug (such as docetaxel) use the letter "T." Cyclophosphamide 
(Cytoxan), fluorouracil (5-FU), and methotrexate (MTX) are standard cancer drugs 
used in many breast cancer chemotherapy regimens. 
Chemotherapy regimens usually consist of 4-6 cycles of treatment given over 3-6 
months. Common chemotherapy regimens for early-stage breast cancer include: 
 AC (Doxorubicin and cyclophosphamide) 
 AC followed by T (Doxorubicin and cylophosphamide followed by 
paclitaxel) 
 CAF (Cyclophosphamide, doxorubicin, and 5-FU) 
 CMF (Cyclophosphamide, methotrexate, and 5-FU) 
 TAC (Docetaxel, doxorubicin, and cyclophosphamide 
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3. CELL CYCLE 
3.1. CELL CYCLE AND CANCER 
More than 50 years have passed since Howard and Pele in 1951 first described the 
cell cycle and its phases. Nevertheless, there are only more recent studies that have 
revealed that the cell cycle is a highly conserved and ordered set of events, 
culminating in cell growth and division. Cell cycle is tightly controlled by many 
regulatory mechanisms that either permit or restrain its progression (Gali-Muhtasib 
and Bakkar, 2002). Therefore, cell cycle is a process in which it grows and divides to 
create two genetically identical cells. In mammalian cells, the whole cell cycle takes 
around 24 hours from start to finish. Some cells, such as skin cells, are constantly 
going through the cell cycle while other cells may divide rarely as the neurons that 
don‟t grow and divide. The basic cell cycle consists of four distinct phases (Figure 
6):  
 
Figure 6. Phases of cell cycle 
 
- G1 phase (the interval between the M phase and the beginning of S phase) in  
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  which cells respond to extracellular cues that ultimately determine whether cells  
  will make the decision to replicate DNA and divide or, alternatively, to exit the cell  
  cycle into a quiescent state (G0). G1 phase is characterized by metabolic changes  
  that prepare the cell for division; in fact this phase is marked by synthesis of various  
  enzymes that are required in S phase, mainly those needed for DNA replication.  
  Duration of G1 is highly variable, even among different cells of the same species  
  (Smith and Martin, 1973) 
- S phase (S for synthesis) in which the genetic material is duplicated (each 
chromosome now consist of two sister chromatids); 
- G2 phase (the interval between the end of S phase and the beginning of M phase)  
  in which metabolic changes assemble the cytoplasmic materials necessary for  
  mitosis and cytokinesis; 
the period between mitotic division, which consists of G1, S, G2 phases, is known   
as interphase; 
- M phase (M for mitosis) in which phase a nuclear division (mitosis) is followed by  
  a cell division (cytokinesis) (Gorbsky, 1997). 
Mitosis is conventionally divided into five stages (Figure 7): 
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Figure 7. Steps in mitosis 
 
- prophase: in which the nuclear membrane breaks and the centrosome duplicate 
itself to form two daughter centrosome that migrate to opposite ends of the cell; the 
centrosomes organized the production of microtubules that form the spindle fibers 
that constitute the mitotic spindle; each replicated chromosome can now be seen to 
consist of two identical chromatids, or sister chromatids, held together by the 
centromere; 
- prometaphase: in which the chromosome migrate to the equatorial plane in the 
midline of cell, in the metaphase plate; 
- metaphase: in which the chromosome align themselves along the metaphase plate 
of the spindle apparatus; 
- anaphase: in which the centromeres divide and the sister chromatids are pulled 
apart and pulled in opposite sides of the cell; 
- telophase: in which the nuclear envelope reassembles around the two new set of 
separate chromosome to form two nuclei; 
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Cytokinesis is the time in which the other components of the cell (membranes, 
cytoskeleton, organelles) are distributed to the two daughter cells. 
 
When cells cease proliferation, either due to specific antimitogenic signals or to the 
absence of proper mitogenic signalling, they exit the cycle and enter a non-dividing, 
quiescent state known as G0. 
Activation of each phase is dependent on the proper progression and completion of 
the previous one. In the typical dividing eukaryotic cell, G1 phase lasts 
approximately 15 hours, S phase 6 to 8 hours, G2 phase 3 to 6 hours, and mitosis 
about 30 minutes, although the exact length of each phase varies with the cell type 
and growth conditions (Pardee et al., 19878; Murray and Hunt T, 1993).  
In the cell, there are control systems, independent by cell cycle events, that operate 
even if those events fail or in response to genetic damage. Both intracellular 
(oncogenes and anti-oncogenes) and extracellular (environmental signals, growth 
factors) inputs trigger molecular events that regulate normal progress through the 
stages of the cell cycle. 
The main families of intrinsic regulatory proteins that play key roles in controlling 
cell cycle progression are the cyclin-dependent kinases (CDKs), cyclins, CDK 
inhibitors (CDKIs) and are actively involved two tumor suppressor protein, p53 and 
pRb (Gali-Muhtasib and Bakkar, 2002). 
The cyclin-dependent kinase (CDK) is a family of serine/threonine protein kinases 
(Morgan, 1997) that regulates cell cycle and mRNA transcription and processing. All 
CDKs share the feature that their enzymatic activation requires the binding of a 
specific regulatory cyclin subunit (Table 2).  
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Phase Cyclin CDK 
G0 C CDK3 
G1 D,E CDK4, 2, 6 
S A,E CDK2 
G2 A CDK2,1 
M B CDK1 
Table 2. Cyclins and CDKs by cell cycle phase 
 
CDK regulators can also control cell-cycle commitment: they include activators, 
mainly the cyclins, and inhibitors, generically known as CDKI.  
The cyclins are a family of proteins centrally involved in cell cycle regulation and 
structurally identified by conserved „cyclin box‟ regions. 
Cyclins are regulatory subunits of holoenzyme CDK complexes controlling 
progression through cell cycle checkpoints by phosphorylation and inactivating 
target substrates and they are so named because their concentration varies in a 
cyclical fashion during the cell cycle (Figure 8). 
 
Figure 8. Expression of human cyclins through the cell cycle 
 
Introduction 
45 
 
There are several different cyclins that are active in different parts of the cell cycle 
and that cause the CDK to phosphorylate different substrates. There are also several 
"orphan" cyclins for which no Cdk partner has been identified. 
There are two main groups of cyclins: 
◊ G1-S cyclins: these ccyclins rise in late G1 and fall in early S phase. The Cdk- 
G1/S cyclin complex begins to induce the initial processes of DNA replication, 
primarily by arresting systems that prevent S phase Cdk activity in G1; they are 
Cyclins D and E involved in the transition from G1 to S phase (bind to CDK4 an 
CDK 6) and Cyclins A, active in S-phase (bind to CDK2); 
◊ G2/M cyclins: M cyclin concentrations rise as the cell begins to enter mitosis and 
the concentrations peak at metaphase. Cell changes in the cell cycle like the 
assembly of mitotic spindles and alignment of sister-chromatids along the spindles 
are induced by M cyclin-CDK complexes. The destruction of M cyclins during 
anaphase causes the exit of mitosis and cytokinesis. They are Cyclins B (bind to 
CDK1). 
 
The CDK inhibitors (CDKI) are protein that that serve as negative regulators of the 
cell cycle and stop the cell from proceeding to the next phase of the cell cycle, 
interacting with the cyclin-CDK complex blocking the kinase activity. There are two 
major CDKI families: the INK4 family (named for their ability to inhibit CDK4), 
comprising four members (p16
 Ink4a
, p18
 Ink4c
, p15
 Ink4b
, p19
Ink4d
) which  inhibit the 
activity of cyclin D-dependent kinases to prevent the phosphorylation of pRb family 
proteins and Cip/Kip family comprising three members (p21
Cip1
, p27 
Kip1
, p57 
Kip2
). 
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In addition to intrinsic controls, many external controls affect cell division. For 
example, the hormone estrogen affects the development of a wide variety of cell 
types in women and it exerts its effects on a receptive cell by binding to a specific 
receptor protein on the cell's nuclear membrane, initiating a cascade of biochemical 
reactions that lead to changes in the cell-cycle program. Also growth factors, such as 
TGF-β, PDGF, EGF and IL-2, stimulate cell proliferation and cell cycle progression.  
The independence from specific growth factors is a common occurrence in 
transformed cells, which leads to a growth advantage on normal cells (Baserga et al., 
1993). 
To ensure proper progression through the cell cycle, cells have developed a series of 
checkpoints that prevent them from entering into a new phase until they have 
successfully completed the previous one (Hartwell and Weinert, 1989). It is likely 
that newly divided or quiescent cells must also pass certain checkpoints before they 
can enter the cycle. For instance, cells must make sure that they have reached their 
homeostatic size, otherwise cells will become smaller with each round of division. 
The checkpoints are three in the normal cells:  
- the G1-S checkpoint (or Start or restriction point) is located between mid and late 
G1 phase, just before entry into S phase. This is the point at which the cell ascertains 
whether it has received the necessary growth signals so that it can pass out of G1 into 
S phase, replicates its DNA and completes one round of cell division (Planas-Silva 
and Weinberg, 1997). If the cell has not received the appropriate cues, it will not pass 
the restriction point and will instead enter G0.  
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The cell may also arrest later in S phase due to incomplete DNA replication or DNA 
damage. The main controllers of this restriction point, which are pRb (retinoblastoma 
protein), p53, p16INK4a, be discussed in detail in the next section; 
- the G2 checkpoint is located at the end of G2 phase, controlling the triggering of 
M phase. This point monitors the fidelity of DNA replication and is also an important 
sensor of DNA damage; 
- the metaphase checkpoint (or spindle checkpoint) is activated during mitosis and 
control appropriate formation of spindle microtubule structure, chromosome 
alignments, sister-chromatids segregation, and completion of mitosis and cytokinesis.  
 
If these cell cycle checkpoints are not in place then inappropriate proliferation can 
occur, which is one of the hallmarks of cancer. Several genes encoding regulatory 
activities that govern the cell cycle are targets for genetic and epigenetic alterations 
that underlie the development of many human cancers (Sherr, 1996). Molecular 
analysis of human tumours has shown that cell-cycle regulators are frequently 
mutated in human neoplasias (Figure 9), underscoring the importance of cell-cycle 
regulation in the prevention of cancer. These alterations include overexpression of 
cyclins (i.e. D1 and E1) and CDKs (i.e. CDK4 and CDK6), as well as loss of CDKI 
(i.e. p16, p15 and p27) and pRb expression. Tumour-associated changes in the 
expression of these regulators frequently result from chromosome alterations 
(amplification of cyclin D1 or CDK4, translocation of CDK6 and deletions of INK4 
proteins or pRb) or epigenetic inactivation (methylation of INK4 or RB1 promoters) 
(Sherr, 2000; Wölfel et al., 1995). 
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Figure 9. Mutations of G1-S regulators in human cancer 
 
 
3.2. THE p53, pRb AND p16INK4a PATHWAYS IN CANCER 
Most, if not all, human cancers contain genetic alterations in the p53, pRb and 
p16INK4a tumor suppressor pathway (Hanahan and Weinberg, 2000). 
 
The p53 tumour suppressor (known as “the guardian of genome”) is a transcription 
factor responsible for the blockage of the cell cycle at the G1/S and G2/M 
checkpoints and/or inducing apoptosis in proliferating cells that are subjected to a 
variety of stressful events. 
p53 belongs to a small family of related proteins that includes two other members: 
p63 and p73. Although structurally and functionally related, p63 and p73 have clear 
roles in normal development (Irwin, M. S. & Kaelin, W. G. p53 family update: p73 
and p63 develop their own identities. Cell Growth Differ. 12, 337–349 (2001).), 
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whereas p53 seems to have evolved in higher organisms to prevent tumour 
development. The steady state level of p53 is low in the absence of cellular stress and 
its turnover rate is rapid (less than 30 minutes). However, in response to a variety of 
stress signals, both intrinsic and extrinsic, the p53 protein is activated and, in turn, it 
can induce its downstream pathway. Gamma or UV radiation, alkylation or 
depurination of DNA, reaction with oxidative free radicals, ribosomal stress, 
oncogene activation, chemotherapeutic agents, altering DNA in different ways, but 
also hypoxia, microtubule disruption and loss of normal cell contacts cause damages 
and different repair mechanisms are employed by the cell. In each case, the damage 
activates and stabilizes p53, which migrates to the nucleus. These effects are 
determined by post-translational modifications of p53, such as phosphorylation, 
acetylation, methylation, ubiquitination or sumolation (Figure 10)  (Appella and 
Anderson, 2001). 
 
Figure 10. Diversity of cancer-related signals that activate p53 contributes to the central role the 
p53 protein as a tumor suppressor. 
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Different types of DNA damage activate different enzyme activities that modify the 
p53 protein on different amino-acidic residues. These modifications alter the p53 
protein in two ways: first, by increasing the half-life of p53 in the cell (from 6-20 
minutes to 1 hours), and this results in a 3-10 fold increase in p53 protein quantity in 
the cell; second, by enhancing the ability of p53 to bind to DNA sequences. 
In fact, once that p53 is activated, it binds to specific DNA sequences and activates 
genes that are part of one of three stress response programs: cell cycle arrest (such as 
p21, GADD45 genes) to buy time to repair the DNA damage, cellular apoptosis 
(such as Bax, Puma genes), the programmed cell death when DNA damage proves to 
be irreparable, senescence (such as CSPG2 gene) promoting irreversible growth 
arrest (Figure 11) (Balint and Vousden, 2002; Giaccia and Kastan, 1998). 
 
 
Figure 11. Downstream targets of the p53 transcription factor mediate its different biological 
outcomes. 
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One of the genes induced by p53 is p21, which play a pivotal role in G1 arrest by 
inhibiting cyclin D-CDK4/6 activity, reducing the pRb phosphorylation and blocking 
cell cycle.   
Furthermore, p53 is regulated by different regulatory mechanisms. The p53 is a 
short-lived protein, its level kept low in most normally proliferating cells by rapid 
protein degradation. One of the key components regulating p53 stability is MDM2 
(murine double minutes 2), a protein that functions as an ubiquitin ligase for p53, 
promoting the rapid degradation of p53 via the ubiquitin-proteasome pathway 
(Kubbutat et al., 1997). MDM2 is also a transcriptional target of p53 and therefore it 
functions in a negative regulatory feedback loop in which p53 activates the 
expression of MDM2, which in turn inactivates p53 by targeting p53 for degradation 
(Momand et al., 1992). Therefore, the function of p53 is to prevent the propagation 
of abnormal cells at risk of becoming cancer cells, blocking their cell cycle 
progression. The loss of p53 function occurs in > 50% of human cancer, thus 
representing the most frequent gene alteration in cancers (Harris and Levine, 2005; 
Vousden and Lu, 2002), by various mechanisms, including lesions that prevent 
activation of p53, missense, deletions and insertions mutations within the TP53 gene 
(which encodes p53) itself or mutations of downstream mediators of p53 function.  
In human breast tumors p53 gene mutation is the most common genetic alterations 
identified: mutations or over-expression of p53 protein in up to 52% of primary 
breast cancer specimens were observed indicating p53 as potential marker for 
studying the relationship between mutant p53 expression and tumor development, 
progression, and response to treatment and disease outcome.  
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Of the remainder breast carcinomas in which p53 gene mutation is not observed, half 
or more express wild-type p53 protein at high levels. In these cases, events 
independent of direct mutation of p53 may interfere with the normal function of the 
tumor suppressor during mammary tumorigenesis. Several studies have suggested 
that p53 status is an important determinant of tumour responsiveness to anti-
neoplastic agents (Lowe et al., 1994; Clahsen et al., 1998). Specific mutations in p53 
have been associated with poor response to primary systemic therapy (Aas et al., 
1996) or overall survival (Borresen et al., 1995). Since many anti-cancer agents 
function is to activate cell death/apoptosis (Carson and Ribeiro, 1993), loss of normal 
p53 function can potentially result in the relative resistance of breast cancers to 
chemotherapeutic agents, due to the loss of the apoptotic properties of p53 (Bates 
and Vousden, 1999). This is possibly the reason why alterations of the p53 gene in 
breast cancer are associated with an unfavorable prognosis. Therefore, designing 
alternative treatment strategies aimed specifically at either restoring p53 function, or 
inducing optimal cellular response to damage, is a promising, rapidly-developing 
field in cancer research. Among these strategies are the gene therapy transfer of a 
„minigene‟ encoding wild-type p53 with a viral vectors, or designing p53-
reactivating drugs in tumors with an inactived p53, or restoring the p53 function by 
alternative approaches which aim to promote p53 transcriptional and tumour 
suppressor activities.  
 
The pRb pathway consists of five families of proteins: CDKI, cyclin-D, CDK 
(CDK4 and CDK6), pRb-family of pocket protein (pRb, p107, p130), E2F-family of 
transcription factors (Figure 12).  
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Figure 12. Schematic of pRb pathway in cell cycle control. 
 
The pRb pathway is the major controller of cell cycle progression and of cell 
proliferation, and its constituents are activated by growth-promoting and inhibited by 
growth-suppressing signals. In quiescent cells, pRb is in its actively growth-
suppressing hypophosphorylated state, and inhibits the cell cycle progression through 
the interaction with E2F factors, a family of transcriptional regulators that control the 
expression of genes whose products are important for entry and progression through 
S phase (Sherr and Roberts, 1999; David-Pfeuty, 2006). In response to mitogenic 
factors, pRb is inactivated through its phosphorylation on multiple sites. In its hyper-
phosphorylated form, pRb leaves the E2Fs free to activate the target genes involved 
in cell cycle progression (e.g. Cyclins E) and DNA synthesis (i.e. thymidylate 
synthase, dihydrofolate reductase, thymidine kinase, ribonucleotide reductase, myc 
and DNA polymerase α), thus suggesting that E2F family member may be 
responsible for transversing the G/S checkpoint (Harbour et al., 1999; Zhang et al., 
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2000). pRb phosphorylation is triggered in the early G1 phase by the cyclin D–CDK-
4 and CDK-6 complexes and is completed, at the end of the G1 phase, by cyclin E–
CDK-2 complexes. The activities of the CDKs are in turn constrained by the CDK 
inhibitors: CDK-4 and CDK-6 are inhibited mainly by p16(INK4a), whereas CDK-2 
is negatively regulated by p21 and p27 (Sherr and McCormick, 2002), p53 
negatively affects the cell cycle progression by inducing the p21 expression. The 
components of the regulatory machinery that controls G1-S phase transition behave 
as tumor suppressors or proto-oncogenes and are frequently altered in cancer cells. 
RB1 (the gene encoding pRb) mutation or deletion, p16INK4a mutation and/or 
epigenetic silencing, and cyclin D1 or CDK4 overexpression and/or amplification 
characterize many human cancers (Figure 13) (Sherr and McCormick, 2002). 
 
 
Figure 13. Example of alterations in the pRb pathway 
 
These changes, causing either pRb loss or hyperphosphorylation, render the major 
control mechanism of the G1-S phase checkpoint out of order. Indeed, inactivation of 
the pRb tumor-suppressor pathways is associated with tumorigenesis and 
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characterizes a large fraction of many types of cancers (Sherr, 2000; Vogelstein and 
Kinzler, 2004). 
 
Loss of normal pRb function is associated with 20% of human breast cancers. In the 
80% of breast carcinomas in which pRb gene mutation is not observed, alterations in 
components of the signaling pathways that regulate pRb are frequently noted (Varley 
et al., 1989). For example, cyclin D1 and cyclin E overexpression, CDK4 gene 
amplification, or deletion of p16 have all been associated with primary breast 
carcinomas. Nearly 50% of invasive breast cancers examined have elevated cyclin 
D1 expression (Buckley et al., 1993). 
 
p16INK4a (also known as CDKN2A) belongs to the INK4 family, which includes 
p16
 Ink4a
, p18
 Ink4c
, p15
 Ink4b
, and p19
Ink4d
. It is an inhibitor of cyclin-CDK4 or cyclin-
CDK6 complexes, blocking their kinase activity, and so interfering with the pRb 
phosphorylation, and inhibiting the progression to the S-phase of cell cycle (Ruas 
and Peters, 1998). p16INK4a is a potent tumor suppressor and alterations leading to 
its inactivation result in the deregulation of cell proliferation through loss of G1 
arrest control, contribute to the formation of cancer and may influence tumour 
response to chemotherapy. In fact p16INK4a is commonly mutated, deleted or 
hypermethylated, resulting in the reduction or absence of its expression, in human 
cancers (Medema et al., 1995).The absence of p16INK4a expression is seen 
predominantly in cells that retain wild-type pRb (Otterson et al., 1994). However, 
p16INK4a can be up-regulated or overexpressed in cancer cell lines and tumors in 
which pRb is dysfunctional (Dublin et al., 1998) providing evidence for a negative 
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feedback loop in which the functionally inactive pRb fails to sequester transcription 
factors, which, in turn, induce p16INK4a gene expression. 
The ability of p16INK4a to arrest the cell cycle in G1 phase depends upon the 
presence of a functional pRb, implying that by inhibiting cyclin D-dependent 
kinases, pRb remains hypophosphorylated and able to repress transcription of S-
phase genes (Medema et al., 1995). The loss of p16 expression is necessary to bypass 
the G1 checkpoint in cancer cells during tumor progression (Shapiro et al., 1998). In 
mammary carcinomas, the etiological role of p16 is far from understood: although 
p16 inactivation is observed in several breast cancer cell lines, mutation or deletion 
of the p16INK4a gene are rare events in breast cancer (Quesnel et al., 1995). The 
only study available in the literature specifically examining the prognostic 
significance of p16INK4a in breast cancer reported that poor outcome was associated 
with high expression of p16 protein assessed by immunohistochemical staining 
(Dublin et al, 1998). 
 
The hallmark of cancer is deranged growth control (Pardee et al., 1978), because 
checkpoints are defective in cancer cells (Hartwell and Kastan, 1994). As previously 
stated, control mechanisms are often lost due to mutations in tumor suppressor genes, 
e.g. mutated p53 gene, or alterations in one of the pRb pathway components. A 
relationship between pRb and p53 exists in cell cycle regulation based on the action 
of the two genes regulated by p53: MDM2 and p21. 
MDM2 contains a p53-binding site, but also a pRb-binding site: by interacting with 
pRb, MDM2 restrains its functions by altering the conformation of the pocket region 
(Xiao et al., 1995). It is postulated that overespression of MDM2 inactivates both 
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p53 and pRb. p21 is an effector of cell cycle arrest in response to activation of the 
p53 G1 phase checkpoint pathway that acts through inactivation of the cyclin-CDK 
complexes that are responsible for pRb phosphorylation.  
 
These findings imply a potential link between pRb (p16-pRb-cyclin D1) and p53 
(p53-MDM2-p21) pathways in cell cycle regulation and apoptosis and it play a 
critical role in tumorigenesis (Figure 14). 
 
Figure 14. Schematic representation of the molecular networking model for p53 and pRb 
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4. AIMS OF THE THESIS 
 
 
Chemotherapy is used to treat various tumor types, including breast cancers; 
chemotherapeutic agents kill cancer cells in different ways, inducing cell cycle arrest 
and/or apoptosis. Cells respond to drug-induced damages mainly by activation and 
stabilization of p53 protein and its downstream pathway (Johnstone et al., 2002).  
Because chemotherapy commonly induces p53 activation, as a matter of principle, 
the presence of a normally functioning p53 in cancer cells could be important for 
both the response to treatment and the prognosis of patients. However, the 
assessment of p53 status has produced contradictory results regarding its 
prognostic/predictive value in human breast cancer (Hall and McCluggage, 2006). 
We hypothesized that these conflicting results could be a consequence of the fact that 
in cancer cells the p53-downstream pathway may be altered, nullifying or changing 
the effect of p53 stabilization after chemotherapy treatment. The most important 
downstream pathway of p53 is represented by pRb, which is often altered in cancer 
cells, influencing the p53-mediated effect of chemotherapy (Knudsen and Knudsen, 
2008). Cancers characterized by pRb alteration, from the clinical point of view, are 
generally more aggressive than those with a normally functioning pRb pathway 
(Cordon-Cardo, 1995) probably because the pRb inactivation causes chromosome 
instability, genetic changes facilitating tumor progression and an up-regulation of 
proliferation cell rate. Moreover, it is also known that the pRb status influences the 
response to DNA-damaging agents in human breast cancer cell lines and in 
xenografts models (Bosco et al., 2007). In order to gain information on the influence 
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of the pRb status in p53-mediated response to chemotherapy, we conducted a 
prospective study on series of patients with primary breast cancer treated with 
chemotherapy, in which we investigated their clinical outcome according to the p53 
and pRb status. We also evaluated the role of pRb status on the p53-mediated 
response to chemotherapeutic drugs in human cancer cells lines treated either with 5-
FU plus MTX or doxorubicin where pRb was down-regulated. Since, in this study 
we demonstrated that tumors characterized by pRb loss were more sensitive to 
chemotherapy independently by p53 status, we then investigated the effects on cell 
cycle progression of pRb deficiency in cancer cell lines after chemotherapy 
treatments.  
There is evidence that a particular subtype of breast carcinomas, the triple-negative 
breast cancer (TNBC), is very sensitive to chemotherapy than other tumor subtypes 
(Reis-Filho and Tutt, 2008). Since we have shown that breast cancers lacking pRb 
expression were more sensitive to adjuvant chemotherapy, we sought to ascertain 
whether in TNBCs, the high sensitivity to chemotherapeutic drugs could be due to 
the loss of pRb. 
Therefore we evaluated the prevalence of pRb loss and the chemosensitivity in a 
large series of triple-negative breast cancer patients treated with chemotherapy, in 
according to the pRb status. We also studied the relevance of pRb loss on 
chemosensitivity in a triple-negative derived cell line. 
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5. MATERIALS AND METHODS 
 
 
5.1. Patients 
We studied a total of 518 consecutive patients who underwent surgical resection for 
primary invasive breast carcinoma at the Department of Surgery, University of 
Bologna, between 1991 and 1995. Patients‟ age ranged from 25 to 89 years, with an 
average (±SD) of 60 (±12.9) years (median value, 61 years). Tumors were 
histologically classified and staged according to the WHO and the Unio 
Internationale Contra Cancrum tumor-node-metastasis systems, respectively. 
Histologic grading (G) was done in ductal carcinomas according to Elston and Ellis 
(Elston and Ellis, 1991). Due to patient age, axillary dissection was not done in 7 
patients (1.3%): in the remaining 511 cases, axillary lymph node metastases were 
reported as absent (N0) or present (N+). Estrogen receptor (ER) and progesterone 
receptor (PR) status; Ki67 antigen expression; and p53, HER2, and pRb status were 
assessed on histologic sections by standard immunohistochemistry, as reported 
below. All immunohistochemical analyses were done at the time of diagnosis. 
Patients were then regularly followed up every 6 mo for a median observation time 
of 109 mo (range 4-142 mo). 
The present study was approved by the Senior Staff Committee, the board, which, at 
the time of patient enrollment, regulated non interventional studies and was 
comparable with an institutional Review Board. 
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5.2. Adjuvant treatments 
Three hundred and forty-two patients underwent mastectomy and 176 patients 
underwent conservative breast surgery. One hundred and forty-five received six 
cycles of the cyclophosphamide, methotrexate, and 5-FU (CMF) chemotherapy 
regimen that was given on days 1 and 8 of each treatment cycle. The dose of 
cyclophosphamide and fluorouracil was 600 mg/m
2
 of body surface area and the 
dose of methotrexate was 40 mg/m
2
. Each of the three drugs was repeated every 28 
d. 231 patients who did not receive systemic chemotherapy received adjuvant 
endocrine therapy alone (tamoxifen, 20 mg daily, for at least 2 y). A total of 49 
patients received radiotherapy only and 93 patients did not receive any kind of 
adjuvant therapy. 
 
5.3. Immunohistochemical assessment 
From each case, one block of formalin-fixed, paraffin-embedded tissue was selected, 
including a representative tumor area. Four-micrometer-thin serial sections were cut, 
collected on 3-ethoxy-aminoethyl-silane-treated slides, and allowed to dry overnight 
at 37°C. Tissue sections were then processed for immunohistochemistry and the 
immunostaining reaction was then developed according to the SABC (Streptavidin-
Biotin-Peroxidase Complex) method, combined with antigen retrieval pretreatment 
in citrate buffer solution (pH 6), and highlighted using a peroxidase/ 3,3‟-
diaminobenzidine (DAB) enzymatic reaction. 
The following monoclonal antibodies (mAbs) were used: anti-p53 (clone BP53-
12.1), anti-Ki67 (clone MIB-1), anti-HER2 internal domain (clone CB11), anti-ER 
(clone 1D5) and anti-progesterone receptor (anti-PR; clone 1A6), all from BioGenex 
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Laboratories. pRb immunostaining was assessed using two different mAbs: clone 
G3-245 (BioGenex Laboratories), which specifically recognizes the phosphorylated 
pRb form, and clone 1F8/Rb1 (Neomarkers, Lab Vision), which identifies all forms 
of pRb (phosphorylated as well as unphosphorylated or underphosphorylated).  
The pRb status was assessed by evaluating both the percentage of cells with  
phosphorylated pRb and of cells exhibiting total pRb.  
The pRb phosphorylation level was evaluated using an anti-pRb monoclonal 
antibody (mAb) (clone G3-245) that specifically recognizes ppRb form. 
The phosphorylated pRb-LI variable was dichotomized using the cutoff point of 
25%, according to Derenzini et al  (Derenzini et al., 2004) in which chose the 25% 
cutoff because pRb hyperphosphorylation is found mainly in the late G1, S, and G2 
phases, whose duration in human cancers is not longer than one quarter of the cell 
cycle length. Therefore, the presence of a pRb LI > 25% is strongly indicative of an 
alteration of pRb phosphorylation control. 
Because in our series 40 cases (7.7%) showed a very low positivity for 
phosphorylated pRb (ppRb LI <1%), these cases were assumed to include two kinds 
of tumors: (a) tumors in which pRb was present but phosphorylated only in a few 
cells and (b) tumors in which both the pRb forms were absent, very likely due to RB1 
deletion. To differentiate between these two groups, the 40 cases were investigated 
for the presence of total pRb, using a specific mAb (clone 1F8/Rb1) that recognizes 
both the phosphorylated and the unphosphorylated or underphosphorylated pRb 
forms. Nine cases showed positive immunostaining in some cancer cells, whereas the 
remaining 31 cases showed no immunostaining. The latter cases were definitively 
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regarded as RB1 deleted and were included in the RB negative (RB-) group. The 
remaining 487 cases were included in the RB positive (RB+) group. 
The p53 status was evaluated by measuring the percentage of immunostained nuclei 
(p53-LI). We considered samples with at least 10% of nuclear staining to be 
characterized by an altered p53 status, according to Esrig et al (Esrig et al., 1993). 
p21 expression was evaluated using anti-p21 mAb (Dako Cytomation, Glostrup, 
Denmark) measuring the percentage of immunostained nuclei (p21-LI). All mAbs 
were applied overnight at room temperature at the predetermined optimal 
concentrations.  
The nuclear immunostaining of ER, PR, Ki67, p53 and pRb was assessed by image 
cytometry, using the Cytometrica program (C&V, Bologna, Italy) as detailed by 
Faccioli et al. (Faccioli et al., 1996). Staining was expressed as the percentage of 
labeled nuclear area over the total neoplastic nuclear area in the section [labelling 
index (LI)]. HER2 membrane immunostaining pattern and intensity were assessed by 
direct microscope evaluation, following the four class scoring system (0, +1, +2, +3) 
according to published protocols (Ellis et al., 2004). For each case, at least 2,000 
cells were evaluated. All the immunohistochemical analyses were performed at the 
time of diagnosis. 
 
5.4. Cell lines and growth conditions 
The human breast cancer cell line MCF-7 was maintained in RPMI 1640 (Euroclone, 
Milan, Italy) supplemented with 10% fetal bovine serum (FBS; Euroclone); the 
human colon cancer cell line HCT-116 and the human breast cancer cell line MDA-
MD-231 were maintained in DMEM supplemented with 10% FBS; the human 
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hepatocellular carcinoma cell line HepG2 was maintained in RPMI 1640 
supplemented with 10% FBS and sodium pyruvate (Euroclone). All cell lines were 
from the American Type Culture Collection (ATCC). FBS was inactivated by heat 
(56°C for 30 minutes). 
All cell lines were cultured in monolayer at 37°C in humidified atmosphere 
containing 5% CO2 in medium with L-glutamine (Euroclone) 2mM, penicillin 100 
U/ mL and streptomycin 100 mg/ mL (Euroclone).  
 
5.5. Production of HCT-116-derived cells with stably inactivated p53 
HCT-116 cells stably expressing p53DD, a truncated, dominant-negative form of 
murine p53 (Shaulian et al., 1995) and the related empty vector-transduced control 
cells (pBABE), were obtained as described by Morgenstern JP and Land H  
(Morgenstern and Land, 1990). These cell lines were maintained in DMEM 
supplemented with 10% FBS and selected with puromycin antibiotic (Sigma-
Aldrich, Milan, Italy). 
 
5.6. Drugs and cell treatment protocols 
A drug cocktail of 5-Fluorouracil (5-FU; Fluorouracil, Teva Pharma B.V. Milan, 
Italy) and methotrexate (MTX; Metotrexato, Mayne-Mayne Pharma, Naples, Italy) at 
doses of 20 μg/ml and 0.1 μg/ml, respectively, was used to treat MCF-7, MDA-MB-
231, HCT-116 wild-type (wt) and HCT-116-derived cell lines. Doxorubicin 
(Doxorubicin Hydrochloride Injection, USP, Pfizer Italia, Rome, Italy) was used at a 
concentration of 1 μM on MCF-7 and MDA-MB-231, 3 μM on HepG2 and 0.3 μM 
on HCT-116-derived cell lines. Both drugs were diluted directly from stock solutions 
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and mixed in RPMI or in DMEM with 10% FBS. Cells were exposed to either 
doxorubicin or 5-FU plus MTX for 1 or 2 h at 37°C. After the drug treatments, in an 
initial set of experiments, the cells were washed extensively with PBS, fed with fresh 
medium for 6 h and then harvested. In a second set of experiments the cells were 
exposed to the drugs for 2 h daily for 4 consecutive days and fixed in formalin 24 h 
after the last treatment. 
 
5.7. Genes silencing by RNAi transfection 
The day before transfection, cells were seeded in antibiotic-free growth medium. 
Transfections were performed with Lipofectamine RNAiMAX (Invitrogen, Carlsbad, 
UK) in Opti-MEM medium (Invitrogen) following the manufacturer‟s protocol. 
After 4 hours, the Opti-MEM is been replaced with the appropriate growth medium. 
Silencing of RB1, TP53 and p16INK4a was obtained by transient transfection of cells 
with specific interferent RNA oligos (RNAi). Transfections were performed with 
Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM medium (Invitrogen) 
accordingly to manufacturer‟s procedures.  RB1 and TP53 genes were silenced using 
Stealth RNAi Select kits (Invitrogen), while sequences of RNAi for p16INK4a 
silencing (Invitrogen) were from Lau et al (Lau et al., 2007). Controls for RB1- and 
TP53-silenced cells were transfected with equivalent amounts of Stealth RNAi 
Negative Control (Invitrogen), while controls of p16INK4a silenced cells were 
transfected with an RNA oligo sequence (obtained by scrambling the sequence of 
p16-specific RNAi) that is not complementary to any known human transcript 
(screened on NCBI BLAST). The concentrations of siRNAs used resulted to be 
lowest one capable to reduce the mRNA levels to at least the 80% of control for 
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duration of 120 h. The RNAi specific for RB1 was used at a final concentration 80 
nM, while those for TP53 and p16INK4a genes in 40 nM concentration. The 
Lipofectamine is being used with a ratio of 1 μL every 15 picomoles of RNAi. 
 
5.8. RNA extraction, cDNA synthesis and real-time RT–PCR analysis 
Cells were harvested and total RNA was extracted from cells 48 and 120 h after 
siRNA transfection with TRI reagent (Ambion, Austin, TX, USA) according to 
manufacturer instructions. The cells were homogenized in TRI Reagent solution, 
collected in eppendorf tubes and incubate for 5 minutes at room temperature (RT). 
After that, the homogenate were centrifuged, incubated with 160 μl chloroform for 
10 minutes at RT to generate the phase separation, re-centrifuged again and the 
aqueous phase containing the RNA was transferred in a fresh tube. The RNA was 
precipitated by adding isopropyl alcohol, incubated at RT for 10 minutes, spinned to 
allowed RNA to precipitate. After discard the supernatant, the gel-like bottom RNA 
was washed in 75% alcohol for washing, centrifuged, air-dried for 10 minutes e 
dissolve in DEPC water. Extracted RNAs were quantified with a Nanodrop 
spectrophotometer (ND1000). The quality of RNA extracted was evaluated 
measuring the A260/A280 ratio. Reverse transcription reactions were performed in a 
25 µl volume using 2 µg of total RNA with a High-Capacity cDNA Archive Kit 
(Applied Biosystems, Foster City, CA, USA) following the manufacturer‟s protocol. 
cDNAs obtained were diluted in DEPC water and were subjected to real-time PCR 
analysis in a Gene Amp 7000 Sequence Detection System (Applied Biosystems) 
using the TaqMan Universal PCR mastermix (Applied Biosystems) diluted in 20 µl 
of total volume for well. For each sample, three replicates were analyzed. Cycling 
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conditions were as follows: 50°C for 2 min, 95°C for 10 min, 45 cycles at 95°C for 
15 s, and 60°C for 1 min.  
Primers and probes for RB1, TP53 and p16INK4a were purchased from Applied 
Biosystems (Assay on Demand); human-β-glucuronidase was used as an endogenous 
control gene (Applied Biosystems). All primers were used at a final concentration of 
5 µM. 
The relative amount of the target gene in the cells transfected with the specific 
siRNAs compared with that of scrambled sequences of transfected cells was 
evaluated by the ΔΔCt method (Schmittgen et al., 2000).  
 
5.9. Proteins extraction and Western blot analysis 
For Western blot analysis, cells were lysed in a lysis buffer consisted of 0.1 M 
KH2PO4 (pH 7.5), 1% Igepal (NP-40), 0.1 mM β-glycerophosphate and complete 
protease inhibitor cocktail (Roche Diagnostics) 1X. Cells were incubated 25 min on 
ice and centrifuged at 14,000xg for 25 minutes at 4°C. After the supernatants were 
collected for analysis. Protein concentrations in supernatants were evaluated using 
Bradford assay (using Bio-Rad Protein Assay). All steps were done at 4°C.  
For each sample, 30 µg of lysate proteins (or 50 µg to assess protein expressed little) 
were resuspended in Laemmli buffer. Denatured protein samples were separated in 
10% or 14% SDS polyacrylamide gels and transferred to cellulose nitrate membranes 
(Hybond C Extra, Amersham). Filters were then saturated with 5% non fat dry milk 
powered dissolved in TBS-T solution for 1 h at room temperature. TBS is constituted 
by 20 mM Tris-HCl, 137 mM NaCl (pH 7.6) and is added 0.1% Tween 20 (Sigma) 
for the final TBT-T solution. After the saturation of the membranes are washed with 
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TBS-T (2 washes of 5 minutes) at RT and incubated overnight at 4°C with primary 
antibodies in 3.5% bovine serum albumin TBS-T. The following antibodies were 
used: anti-total pRb (1:200, clone 1F8; Lab Vision Corporation), anti-phospho pRb 
(1:250, Ser780, Cell Signalling Technology, Beverly, MA, USA), anti-p16 (1:200, 
Santa Cruz Biotechnology), anti-p53 (1:1000, clone BP53-12, Novocastra), anti-p21 
(1:100, clone SX118, Dako Cytomation), anti–phospho-H2AX histone (1:1000, 
Ser139, clone 20E3, Cell Signaling Technology) and anti-β-actin (1:4000, Sigma 
Chemical Co.). The next day, the membranes were washed 1x10 min and 2x5 min in 
TBS-T to remove unbound antibody, and were incubated for 1 h in the presence of 
horseradish peroxidase–labeled secondary antibody (dilution 1:10.000 in 5% milk 
TBS-T) at RT. After 3 washes of 10 minutes, the horseradish peroxidase activity was 
detected using an enhanced chemiluminescence kit ECL (GE) and was revealed on 
Hyperfilm enhanced chemiluminescence films (Amersham). The intensity of the 
bands was evaluated with the densitometric software GelPro analyzer 3.0 (Media 
Cybernetics).  Normalization was made against β-actin expression. 
 
5.10. Immunocytochemical analysis  
HCT-116-derived and MCF-7 cells seeded on glass coverslips were silencing and 48 
h after the end of the silencing procedure were fixed and permeabilized in PBS 
containing 2% paraformaldehyde and 1% Triton X-100 for 10 minutes at room 
temperature; after this process the cells were washed 3 times in PBS. For 
immunocytochemical staining, cells were treated with 1.5% H2O2 for 5 min in the 
dark in order to suppress endogenous peroxidase activity. After this the slips were 
washed in PBS. The slips were incubated for 30 minutes at room temperature in PBS 
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containing 1% bovine serum albumin (BSA) to block aspecific staining, then washed 
and incubated overnight with primary anti-p53 monoclonal antibody (1:150, clone 
BP53-12, Novocastra) and anti-pRb monoclonal antibody (1:150, clone 1F8; Lab 
Vision Corporation) diluted in PBS containing 1% BSA at 4°C in a humidified 
chamber. After overnight incubation, slips were washed in PBS and incubated first 
with a biotinylated secondary antibody (Vector Laboratoires) in PBS 1% BSA for 30 
min, washed and then incubated with the streptavidin-peroxidase conjugate (Biospa) 
in PBS 1% BSA for 30 min. The streptavidin-peroxidase complex was visualized by 
dark incubation with diaminobenzydine DAB (Sigma-Aldrich) for 6 minutes.  The 
reaction is blocked by immersing slides in H2Od before to proceed with the 
dehydration and the assembly through sequential steps in 70% ethanol, 96%, 100% 
and xylene. The slides are mounted on the glass with Canada balsam (Sigma). The 
number of positive cells (and hence the proportion of cells in active progression in 
the S phase) is assessed at the microscope in 10 fields per sample using Image-Pro 
Plus software (Media Cybernetics). 
 
5.11. Evaluation of cell population growth 
The crystal violet is a substance of violet color able to bind to DNA and allows to 
assessment of cellular population growth in vitro. 
For the evaluation of cell population growth inhibition after treatment with 
doxorubicin or 5FU-MTX cocktail, 40.000-100.000 cells, depending on cell type,  
were seeded in 12-well plates and drugs were given for 4 consecutive days, 2 h/day, 
starting 48 h after transfection for silenced cells. 24 h after the last drug treatment, 
treated and untreated cells were formalin-fixed for their quantitative growth 
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evaluation, which was carried out using the crystal violet assay as described in 
Carnero et al. (Carnero et al., 2000). Briefly, cells were washed twice with PBS, 
formalin-fixed overnight at 4°C, washed with distilled water and stained for 30 
minutes with 0.1% Crystal Violet in a 20% methanol solution in agitation. Then they 
were washed 4 times in double-distilled water before, photographed, then 
resolubilized in 10% acetic acid solution, for 15 min at room temperature and 
quantified spectrophotometrically at 595 nm, in triplicate. The absorbance is 
proportional to the number of cells because it depends on the quantities of crystal 
violet bound to DNA.  
 
5.12. Evaluation of cell death rate 
Trypan blue is a vital stain obtained from toluidine that is absorbed by the 
macrophages of the reticuloendothelial system and is therefore used for staining cells 
to selectively color dead tissues or cells blue. 
MCF-7 and HCT-116 cells either silenced for RB1 or transfected with scrambled 
sequences were treated with 5-FU and MTX for 1 h. Twenty-four hours after the end 
of drug treatment, the floating cells in the medium of each flask were transferred to 
centrifuge tubes. After detachment of the adherent cells with trypsin, the cells were 
mixed with the corresponding floating cells before centrifugation. The cells were 
then stained with 0.4% trypan blue, and the numbers of trypan blue-positive and 
trypan blue-negative cells were counted on a hemocytometer by light microscopy. 
The experiments were carried out in triplicate. 
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5.13. Cell cycle progression analysis by dual-parameter flow cytometry 
To define the effect of 5-FU and MTX treatment on cell cycle progression, the MCF-
7 cell line was used. Dual-parameter flow cytometry for the simultaneous evaluation 
of DNA content and Bromodeoxyuridine (BrdUrd) incorporation was done. 
Asynchronously growing MCF-7 cells were either silenced for RB1 expression or 
transfected with scrambled sequences. Seventy-two hours after the end of silencing 
procedure, BrdUrd was added at a final concentration of 20 µmol/L for 1 h, and then 
removed and fresh medium was added. Twelve hours later, cells were treated with 5-
FU and methotrexate at doses of 10 and 0.05 µg/mL for 1 h. Cells were harvested 12 
and 24 h later. Untreated cells were used as control. Cells were collected by 
centrifugation and fixed in 70% alcohol. Dual-parameter flow cytometry was done 
by a direct labeling of incorporated BrdUrd by FITC monoclonal antibody followed 
by propidium iodide-DNA counterstaining (Mazzini et al., 1996). Cytofluorimetric 
analyses were carried out in triplicate. Measurements were done by means of a 
Partec PAS II flow cytometer equipped with dual excitation system (argon ion laser 
and HBO100Warc lamp). The 488-nm blue line of the laser has been used to excite 
propidium iodide intercalated into the DNA and the FITC bound to BrdUrd. A 
preliminary instrument alignment and control has always been set up (with rat 
thymocytes stained with propidium iodide) to assure best instrumental analytic 
performances. Immediately before measurement, each sample has been filtered by 
„„Filcons‟‟ 100 (ConsulTS) to remove cell clusters. For a sample measurement, a 
minimum of 20,000 events was acquired. The green (BrdUrd-FITC) and red (DNA-
propidium iodide) fluorescence emission bands were collected, converted, and stored 
as DNA distribution values (histogram) or dual-parameter correlated dot plots by 
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means of a dedicated computer integrated into the instrument. Data were elaborated 
and plotted thanks to the „„Flow Max‟‟ software installed in the computer. Cell cycle 
analyses and the relative statistical data (coefficient of variation of the DNA 
distributions) were done by means of a dedicated software. 
 
5.14. Effect of drug treatment on p53 activation and DNA double-strand breaks 
accumulation 
MCF-7 cells silenced for RB1 and transfected with scrambled sequences were used 
48 h after the end of the transfection procedure. Cells were treated for 1 h with the 5-
FU and MTX and harvested 6, 12, and 24 h after the end of treatment, along with an 
untreated control sample for every condition. The experiments were conducted in 
triplicate. Proteins were extracted for Western blot analysis as described above.  
 
5.15. Statistical analysis 
Differences between groups were evaluated by Student‟s t -test. Comparison of 
proportions between groups was assessed using the two-sample Z-test of proportions. 
Disease-free survival (DFS) curves were generated using the Kaplan–Meier method 
and compared using the log-rank test. Multivariate analyses for DFS were performed 
by applying the Cox proportional hazards regression model. All statistics were 
obtained using the SPSS statistical software package (Statistical Package for Social 
Science, SPSS Inc., Chicago, IL, USA). p<0.05 was regarded as statistically 
significant. 
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5.16. RNAi sequences 
 
RB1: RB1-HSS109090 Fw UCAAGAUUCUGAGAUGUACUUCUGC 
          RB1-HSS109090 Rev GCAGAAGUACAUCUCAGAAUCUUGA 
          RB1-HSS109091 Fw AUAAAGGUGAAUCUGAGAGCCAUGC 
          RB1-HSS109091 Rev GCAUGGCUCUCAGAUUCACCUUUAU 
          RB1-HSS109092 Fw UUCAGUCUCUGCAUGAAGACCGAGU 
          RB1-HSS109092 Rev ACUCGGUCUUCAUGCAGAGACUGAA 
 
TP53: TP53 RNAi-1 Fw CCAUCCACUACAACUACAUGUGUAA 
           TP53 RNAi-1 Rev UUACACAUGUAGUUGUAGUGGAUGG 
           TP53 RNAi-2 Fw CCAGUGGUAAUCUACUGGGACGGAA 
           TP53 RNAi-2 Rev UUCCGUCCCAGUAGAUUACCACUGG 
 
p16INK4a: p16INK4a RNAi Fw 5‟-CGCACCGAAUAGUUACGGUTT-3‟ 
                    P16INK4a RNAi Rev 5‟-ACCGUAACUAUUCGGUGCGTT-3‟. 
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6. RESULTS 
 
 
 
6.1. The p53-mediated sensitivity of cancer cells to chemotherapeutic 
agents is conditioned by status of the pRb protein 
 
 
6.1.1. Assessment of pRb and p53 status  
We analyzed 518 consecutive patients who underwent surgical resection for primary 
invasive breast carcinomas. 
The pRb status was assessed by immunohistochemistry by evaluating the percentage 
either of cells with phosphorylated pRb (using a mAb antibody which specifically 
recognizes the phosphorylated pRb form) or of cells exhibiting total pRb (using a 
mAb antibody which recognizes all form of pRb) as described in detail in Material 
and Methods. We could distinguish three pRb forms: pRb underphosphorylated, pRb 
hyperphosphorylated, pRb deleted (Figure 15). 
The p53 status was evaluated by measuring the percentage of immunostained nuclei 
(p53-LI) as described in Material and Methods and we distinguished two p53 forms: 
p53 normal or wild-type (wt) and p53 alterated (Figure 16). Since there is evidence 
that a series of local cell injuries may occur in tumour tissues causing wild-type p53 
stabilization, in order to identify the cases really characterized by the presence of 
mutated p53, we also evaluated the expression of p21, target of activated p53, in the 
p53-accumulating tumours. In fact, p53-positive tumours, which also express p21, 
might be not characterized by mutated p53 (Nenutil et al, 2005). 
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Figure 15: pRb immunostaining of breast cancers. a-b): pRb immunostaining using pRb 
monoclonal antibody which specifically recognizes the phosphorylated pRb form and (a) is indicative 
of low positivity for ppRb, these cancers are analyzed also for pRb total form (b) is positive for ppRb 
form, these cancers are considered with ppRb. c-d): pRb immunostaining using pRb antibody which 
recognized the total pRb protein. (c) is indicative of normal expression of pRb, (d) is indicative of a 
presumable RB1 gene deletion. In both cases, stromal cells -considered as positive internal controls- 
are clearly immunostained. Bar, 25 µm 
 
 
Figure 16. p53 expression of breast cancers. a-b): Two carcinomas were shown after p53 
immunostaining. Note the absence of expression reported in (a), representing a wild-type expression 
of p53, and the p53 accumulation in (b), representing a p53 alteration 
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The p21 expression was evaluated in the p53-positive tumours by measuring the 
percentage of immunostained nuclei (p21-LI). Fourteen p53-positive tumours were 
found to be characterized by a p21-LI>10% and were therefore excluded from the 
group of p53 putatively-mutated tumours and not considered for the statistical 
analyses. Among the 518 patients, in this study we considered only the 145 patients 
treated with CMF chemotherapy. All the features of population enrolled are reported 
in Table 3. 
Variable 
 
n (%) 
Age 
< 50%  
 50%   
 
63 (43.4) 
82 (56.6) 
Histological diagnosis 
ductal carcinomas   
lobular carcinomas  
medullary carcinomas  
mucoid carcinomas  
sarcomatoid carcinomas  
 
132 (91) 
7 (4.8) 
1 (0.7) 
3 (2.1) 
2 (1.4) 
Tumour size 
pT1  
pT2  
pT3  
pT4  
 
78 (53.8) 
48 (33.1) 
7 (4.8) 
12 (8.3) 
Histological grade  
G1  
G2  
G3  
 
15 (10.3) 
37 (25.5) 
93 (64.1) 
N-status (*) 
N0  
N+  
 
38 (26.8) 
104 (73.2) 
ER-LI 
< 10%  
 10%  
 
58 (40) 
87 (60) 
PGR-LI 
< 10%  
 10%  
 
93 (64.1) 
52 (35.9) 
HER2-status 
negative  
positive  
 
69 (47.6) 
76 (52.4) 
Ki67-LI 
< 20 %  
 20 %  
 
44 (30.3) 
101 (69.7) 
pRb status 
loss  
under- phosphorylated   
hyper-phosphorylated   
 
16 (11) 
85 (58.6) 
44 (30.3) 
p53-LI 
< 10 %  
 10 %  
 
96 (66.2) 
49 (33.8) 
Table 3. Clinical and histopathological characteristics of the enrolled population, treated with 
chemotherapy 
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6.1.2. Relationship between p53 and pRb in tumor prognosis 
We assessed the prognostic relevance of p53 in the whole series and in patients 
according to the pRb status, treated with chemotherapy (Table 4; Figure 17, 18 and 
19). 
 
Treatment 
 
Cases 
(n) 
DFS (%) χ2 p 
Whole series 
p53-LI <10% 
p53-LI ≥10% * 
 
96 
35 
 
57.29 
48.57 
 
0.97 
 
= 0.3259 
Patients with pRb loss 
p53-LI <10% 
p53-LI ≥10% * 
 
3 
11 
 
100 
81.82 
 
0.57 
 
= 0.4492 
Patients with underphosphorylated pRb 
p53-LI <10% 
p53-LI ≥10% * 
 
65 
16 
 
61.54 
31.25 
 
6.63 
 
= 0.0100 
Patients with hyperphosphorylated pRb 
p53-LI <10% 
p53-LI ≥10% * 
 
28 
8 
 
42.86 
37.50 
 
0.75 
 
= 0.6246 
Table 4. Prognostic relevance of p53 in the whole series and in patients considered according to 
the pRb status, investigated by the log-rank test. * Cases with a p21-LI >10% were excluded from 
this group 
 
 
Univariate analysis of DFS indicated that in the whole patient‟s series, in patients 
with pRb loss (Figure 17) and with hyperphosphorylated pRb (Figure 18) the p53 
variable was not associated with the clinical outcome; the only association of p53 
with prognosis was in patients with normally functioning pRb pathway (Figure 19).  
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 Total Number 
Events 
Number 
Censored 
Percent 
Censored 
Significance 
 
p53 wt 3 0 3 100,00  
 
 
 
0,4881 
p53 mutated 13 2 11 84,62 
Overall 16 2 14 87,50 
Figure 17. Disease-free survival curves (Kaplan–Meier estimates) in patients with pRb loss, 
according to p53 status, treated with adjuvant chemotherapy 
 
 
 
 
 
 
 
 
 Total Number 
Events 
Number 
Censored 
Percent 
Censored 
Significance 
 
p53 wt 28 16 12 42,86  
 
 
 
0,8314 
p53 mutated 16 8 8 50,00 
Overall 44 24 20 45,45 
Figure 18. Disease-free survival curves (Kaplan–Meier estimates) in patients with 
hyperphosphorylated pRb, according to p53 status, treated with adjuvant chemotherapy 
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 Total Number 
Events 
Number 
Censored 
Percent 
Censored 
Significance 
p53 wt 65 25 40 61,54  
 
 
 
0,0142 
p53 mutated 20 13 7 35,00 
Overall 85 38 47 55,29 
Figure 19. Disease-free survival curves (Kaplan–Meier estimates) in patients with normally 
function of pRb, according to p53 status, treated with adjuvant chemotherapy 
 
Then, in this group, a multivariate analysis of DFS, including the histopathological 
variables associated with the clinical outcome such as tumor size, histopathological 
grade, node status, ER-, PR- and Ki67-LI, and HER2, demonstrated that p53 status 
was the only factor significantly associated with the DFS (Table 5). Also, without 
correcting the definition of the p53 status by the evaluation of p21 expression, p53-
LI >10% was associated with a worse clinical outcome in the univariate analysis of 
DFS (p=0.0142) and the p53 status was found to be the only factor significantly 
associated with patient clinical outcome in the multivariate analysis of DFS 
(p=0.0190; data not shown). 
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variable Patients treated with chemotherapy 
 
 hazard ratio  
(95% CI) 
p-value 
p53-LI 
< 10%  
 10%  
 
1.00 
3.02 (1.30–7.01)  
 
 
= 0.0099 
Tumor size 
pT1  
pT2  
pT3 + pT4  
 
1.00 
1.72 (0.74–3.99) 
1.93 (0.67–5.55) 
 
 
= 0.2047 
= 0.2194 
Histological grade  
G1  
G2  
G3  
 
1.00 
1.37 (0.27–6.85)  
1.79 (0.32–9.96)  
 
 
= 0.6975 
= 0.5061 
N-status 
N0  
N+  
 
1.00 
1.92 (0.66–5.51)  
 
 
= 0.2250 
ER status (LI) 
 10%  
< 10%  
 
1.00 
0.87 (0.33–2.29)  
 
 
=0.7792 
PR status (LI) 
 10%  
< 10%  
 
1.00 
0. 95 (0.45–2.02)  
 
 
= 0.9109 
HER2-status 
negative  
positive  
 
1.00 
1.70 (0.81–3.55)  
 
 
=0.1562 
Ki67-LI 
< 20%  
 20%  
 
1.00 
1.51 (0.62–3.66) 
 
 
=0.3618 
Table 5. Prognostic relevance of p53 in patients with cancer with normally functioning pRb 
pathway: multivariate DFS analysis 
 
 
6.1.3. Evaluation of p53-mediate chemosensitivity and pRb pathway status in 
cancer cells 
In order to demonstrate the relevance of the pRb pathway status in the p53-mediated 
sensitivity to chemotherapeutic agents, we studied the response to the drugs used in 
breast cancer chemotherapy in human cancer cell lines with either wild-type or 
abrogated p53 function, where the function of pRb was down-regulated either 
inducing a pRb loss either a pRb hyperphosphorylation. Two methods were used to 
inhibit p53 activity: 
- interference with siRNAs specific for TP53 mRNA expression in MCF-7 and 
HepG2 cells; 
Results 
81 
 
- inducement of the expression of an inactive truncated, dominant negative form of 
murine p53 (p53DD) in HCT-116 cells. 
The level of TP53 mRNA was evaluated by Real-Time RT-PCR and it was strongly 
reduced in MCF-7 and HepG2 cells at 48 h after the interference procedure and 
remained very low up to 120 h (Figure 20 a, b, upper). In order to evaluate the effect 
of TP53 mRNA interference on both p53 expression in MCF-7 and HepG2 cells, we 
exposed these cells to doxorubicin and p53 expression was measured by Western 
blot analysis. TP53-silenced cells did not show any accumulation of p53, unlike 
control cells (Figure 20 a, b, lower). 
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Figure 20. p53 inactivation in MCF-7 and HepG2 cells. MCF-7 (a) and HepG2 (b) cells were 
silenced for p53 expression by RNA interference. TP53 mRNA level was evaluated in cells 
transfected with control scrambled sequences (SCR) and in cells silenced for p53 (TP53i), at 48 and 
120 h after the end of the silencing procedure. Note the high reduction of TP53 mRNA in TP53-
silenced cells at both evaluation times. Histograms show the values (mean ± SD) of three independent 
experiments. Representative Western blots of p53 and p21 expression in controls and TP53-silenced 
MCF-7 (Figure 20a) and HepG2 (Figure 20 b) cells, 48 h after the end of the silencing procedure, 
show the absence of p53 and p21 accumulation after doxorubicin treatment in TP53-silenced cells 
(TP53i), as compared to cells transfected with control scrambled sequences (SCR). The expression of 
β-actin was used as a control 
 
 
To check the activity of p53 in the p53DD HCT-116 cells, in which the truncated 
form of p53 induced an accumulation of inactive protein, we evaluated the 
expression of p53 by p53 immunocytochemical staining (Figure 21, upper) and the 
expression of p21, the target of p53, by Western blot analysis after either 5-FU plus 
MTX or doxorubicin treatment. p21 was expressed only in pBABE, not in p53DD 
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HCT-116 cells, demonstrating that both methods were effective to abolishing p53 
activity (Figure 21, lower). 
 
 
Figure 21. p53 inactivation in HCT-116 cells. p53 inactivation in HCT-116 cells was induced by 
expressing a truncated, dominant-negative form of p53 (p53DD). p53 immunocytochemical staining 
exhibits a more intense nuclear positivity in cells expressing p53DD as compared to cells transduced 
with appropriate control sequences (pBABE). Bar = 25 μm. Representative Western blots of p53 and 
p21 expression in pBABE and p53DD HCT-116 cells treated with either 5-FU plus MTX or 
doxorubicin show the absence of p21expression in p53DD HCT-116 cells, as compared to pBABE 
HCT-116 cells 
 
To down-regulate the pRb function, we silenced RB1 in MCF-7 and HCT-116 cells, 
while we induced pRb hyperphosphorylation by p16INK4a silencing in HepG2 cells, 
because in MCF-7 and HCT-116 cells the p16INK4a gene was not expressed 
(Musgrove et al., 1995; Myöhänen et al., 1998). The effect of RB1 silencing in MCF-
7 and HCT-116 pBABE and p53DD cells was evaluated by both Real Time-RT PCR 
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and by Western blot analysis; 48 and 120 h after the RNA interference procedure, a 
strong reduction of RB1 mRNA expression occurred in both cell lines (Figure 22 a). 
Western blot analysis for pRb expression confirmed that 48 h after the RB1 silencing 
procedure, the level of pRb was markedly reduced compared to control samples in 
both cell lines (Figure 22 b).  
 
 
Figure 22. pRb inactivation in MCF-7and HCT-116 cells. a,b) MCF-7 and HCT-116 (pBABE and 
p53DD) cells were silenced for RB1 expression by RNA interference. a) RB1 mRNA level was 
evaluated in cells transfected with control scrambled sequences (SCR) and in cells silenced for RB1 
(RB1i) at 48 and 120 h after the end of the silencing procedure. Note the high reduction of RB1 
mRNA in RB1-silenced cells at both evaluation times. Histograms show the values (mean ± SD) of 
three independent experiments. b) Representative western blots of pRb expression in MCF-7, pBABE 
HCT-116 and p53DD HCT-116 cells, silenced for RB1 expression, 48 h after the end of the silencing 
procedure, show the strong reduction of pRb expression in RB1-silenced cells (RB1i) as compared to 
cells transfected with control scrambled sequences (SCR). pRb is indicated by the pointer, and the 
background staining is indicated by an arrowhead. The expression of β-actin was used as a control. 
The histogram shows the densitometric values (mean ± SD) of three independent experiments. Each 
value concerns the pRb/β-actin ratio, which was set to 100, in untreated cells transfected with 
scrambled sequences. *p < 0.05 
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The silencing of p16INK4a was also confirmed by these two techniques. 48 h after 
the interference procedure, the p16INK4a mRNA level was very low and the 
expression of p16INK4a protein was strongly reduced, while the amount of 
phosphorylated pRb was increased as compared to control, in HepG2 cells (Figure 23 
a, b). 
 
 
 
Figure 23. pRb inactivation in HepG2 cells. a, b) HepG2 cells were silenced for p16INK4a 
expression by RNA interference. a) p16INK4a mRNA level was evaluated in cells transfected with 
control scrambled sequences (SCR) and in p16INK4a-silenced cells at 48 and 120 h after the end of 
the silencing procedure (p16i). Note the high reduction of p16INK4a mRNA in p16INK4a-silenced 
cells at both evaluation times. Histograms show the values (mean ± SD) of three independent 
experiments. b) Representative western blots of p16 and phosphorylated pRb expression in controls 
(SCR) and p16INK4a-silenced (p16i) HepG2 cells, 48 h after the end of the silencing procedure, show 
a high reduction of p16 expression together with the increased level of phosphorylated RB in 
p16INK4a-silenced cells as compared to control HepG2 cells. The expression of β-actin was used as a 
control. The histogram shows the densitometric values (mean ± SD) of three independent 
experiments. In each analysis, values concern the protein:β-actin ratio, which was set to 100, in 
untreated cells transfected with scrambled sequences (SCR). *p < 0.05 
 
 
To assess whether the drug treatment could affect the pRb phosphorylation, after 
p16INK4a-silencing, we evaluated, by Western blot analysis, the expression of p53, 
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p21 and phospho-pRb in control (SCR) or p16INK4a-silenced HepG2 cells treated 
with doxorubicin for 8 hours (Figure 24). We confirmed that the drug treatment 
induced a reduction of phospho-pRb protein level in similarly to not interfered cells. 
 
 
 
Figure 24. Effect of p53 stabilization on p21 and phosphorylated pRb expression in p16INK4a-
silenced HepG2 cells. Cells were treated with Doxorubicin for 8 hours to induce p53 stabilization. 
Representative Western blots of p53, p21 and phosphorylated pRb expression in controls and 
p16INK4a-silenced HepG2 cells, 48 hours after the end of the silencing procedure, show that the drug 
treatment induced an increased level of p53 and p21 expression in controls (SCR) and p16INK4a-
silenced (p16i) cells, as compared to untreated cells. Both in control and in p16INK4a-silenced cells, 
Doxorubicin reduced the level of phosphorylated pRb expression as compared to the respective 
untreated cells. Nevertheless, the expression of phosphorylated pRb after drug treatment appeared to 
be at the same level in p16INK4a-silenced cells as in control, untreated cells. The expression of β 
actin was used as a control. The histogram shows the densitometric values (mean ± S.D.) of three 
independent experiments. In each analysis, values concern the ppRb/β-actin ratio, which was set to 
100, in untreated cells transfected with scrambled sequences. Statistical significance (p<0.05) is 
indicated (*) 
 
We then investigated the long-term effect of 5-FU plus MTX and of doxorubicin 
treatment on the cell population growth in controls and p53-deficient MCF-7 and 
HCT-116, either silenced or not for RB1 expression, and in controls and p53-
deficient HepG2 cells, either silenced or not for p16INK4a expression. 
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In MCF-7 cells, the 5-FU plus MTX, but also the doxorubicin treatment, 
significantly reduced the cell population growth in control TP53-silenced and RB1- 
silenced cells (p<0.01). In cells silenced for both TP53 and RB1 expression, the drug 
treatments induce a growth rate reduction that was significantly greater than caused 
in TP53-silenced cells alone (z=3.300; p<0.001) and not significantly differ from that 
of control cells (Figure 25). 
 
 
Figure 25. Effect of TP53- and RB1-silencing on the growth rate of MCF-7 cells exposed to 
chemotherapeutic agents. The cells were exposed to either 5-FU plus MTX or doxorubicin for 2 h 
daily for 4 consecutive days, and 24 h after the last treatment were formalin-fixed for the crystal violet 
assay for growth rate evaluation. Values relative to samples not treated with drugs were normalized to 
100. Cells were silenced for either RB1 (RB1i+) or TP53 (TP53i+) expression or for both tumour 
suppressors. Cells transfected with scrambled sequences were used as controls (RB1i−, TP53i−). (Left 
panel) 5-FU plus MTX treatment strongly hindered the proliferation of controls and RB1-silenced 
cells, and to a lesser extent that of TP53-silenced cells. After drug treatment, cells with both tumour 
suppressors silenced had a growth rate significantly lower than that of cells silenced for p53 
expression alone. Also, doxorubicin treatment (right panel) strongly reduced the proliferation rate of 
control and RB1-silenced cells. The drug significantly hindered the proliferation rate of TP53-silenced 
cells, although to a lesser extent than in control and RB1-silenced cells. After drug exposure, the 
proliferation rate of cells silenced for both tumour suppressors was significantly lower than that of 
cells silenced for p53 expression alone 
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The result obtained in HCT-116 cells were similar: 5-FU plus MTX treatments 
significantly reduced the growth rate in control and to greater extent of RB1-silenced 
cells, but in p53DD cells, the drug treatments did not significantly reduce the growth 
rate. In RB1-silenced p53DD cells, after the drug treatment, the cell growth reduction 
was significantly greater than that in p53DD cells (z=4.591; p<0.001), being similar 
to that induced in control cells. The effect of doxorubicin treatment on the cell 
population growth rate of HCT-116 cells was similar to those obtained using 5-FU 
plus MTX (Figure 26). 
 
 
Figure 26. Effect of p53 and pRb inactivation on the growth rate of pBABE and p53DD HCT-
116 cells exposed to chemotherapeutic agents. The cells were exposed to either 5-FU plus MTX or 
doxorubicin for 2 h daily for 4 consecutive days, and 24 h after the last treatment were formalin-fixed 
for the crystal violet assay for growth rate evaluation. Values relative to samples not treated with 
drugs were normalized to 100. Effect of 5-FU plus MTX (left panel), and doxorubicin (right panel) 
treatment on cell population growth of pBABE and p53DD HCT-116 cells, whether or not silenced 
for pRb expression. Cells harboring the truncated form of p53 (p53DD) were significantly less 
sensitive to the drugs than pBABE cells. RB1 interference (RB1i+) increased the sensitivity to the 
drugs in pBABE and p53DD cells. After RB1 interference, both drug treatments reduced the growth 
rate of p53DD cells to the same level as that of control pBABE cells 
 
The HepG2 cells were treated only with doxorubicin, as a consequence of their low 
sensitivity to 5-FU plus MTX. The drug significantly reduced the growth rate of 
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HepG2 cells independently of TP53 and p16INK4a expression (p<0.001). After 
doxorubicin treatment, the difference between the growth rate of cells silenced for 
both TP53 and p16INK4a expression and cells silenced for p16INK4a alone was 
significantly lower than that observed between control and TP53-silenced HepG2 
cells (z=7.720;p<0.001) (Figure 27). 
 
Figure 27. Effect of p53 and pRb inactivation on the growth rate of HepG2 exposed to 
doxorubicin. The cells were exposed to doxorubicin for 2 h daily for 4 consecutive days, and 24 h 
after the last treatment were formalin-fixed for the crystal violet assay for growth rate evaluation. 
Values relative to samples not treated with drugs were normalized to 100. Doxorubicin greatly 
reduced the growth rate of control and, to a much lesser extent, of TP53-silenced HepG2 cells 
(TP53i+). The drug exposure also reduced the growth rate of p16INK4a-silenced cells alone 
(p16INK4ai+) and of cells silenced for both p16INK4a and TP53 expression. On the other hand, the 
difference in drug sensitivity between the cells silenced for p16INK4a alone and cells silenced for 
both TP53 and p16INK4a expression was significantly lower than that observed between control and 
TP53-silenced HepG2 cells. The histograms show the values (mean ± SD) of three independent 
experiments 
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6.2. Loss of pRb protein makes human breast cancer cells more sensitive 
to antimetabolites exposure 
 
 
6.2.1. Immunohistochemical definition of pRb status and determination of its 
prognostic value in a large series of primary breast cancer patients 
We studied 518 consecutive patients who underwent surgical resection for primary 
invasive breast carcinomas. The pRb status was assessed by immunohistochemistry 
as described in Material and Methods. The cases regarded as RB1 deleted (31 cases) 
were included in the RB negative (RB-) group; the remaining 487 cases were 
included in the RB positive (RB+) group (Table 6). 
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Table 6. Clinical and histopathological characteristics of the enrolled population. (*) N-status 
was available for 511 cases since, due to patient age, axillary dissection was not performed in 7 
patients 
 
6.2.2. Prognostic value of pRb expression and phosphorylation 
We evaluated the prognostic effect (univariate DFS analysis) of the pRb protein 
expression and phosphorylation in the whole series of patients and in patients who 
variable n (%) 
 
Age 
< 50%  
 50%   
 
117 (22.6) 
401 (77.4) 
Histological diagnosis 
ductal carcinomas   
lobular carcinomas  
medullary carcinomas  
mucoid carcinomas  
sarcomatoid carcinomas  
 
451 (87.1) 
44 (8.5) 
16 (3.1) 
4 (0.8) 
3 (0.6) 
Tumor size 
pT1  
pT2  
pT3  
pT4  
 
323 (62.4) 
142 (27.4) 
13 (2.5) 
40 (7.7) 
Histological grade  
G1  
G2  
G3  
 
59 (11.4) 
339 (65.4) 
120 (23.2) 
N-status (*) 
N0  
N+  
 
275 (53.8) 
237 (46.2) 
ER-LI 
< 10%  
 10%  
 
123 (23.7) 
395 (76.3) 
PGR-LI 
< 10%  
 10%  
 
280 (54.1) 
238 (45.9) 
HER2-status 
negative  
positive  
 
331 (65.0) 
178 (35.0) 
Ki67-LI 
< 20 %  
 20 %  
 
277 (53.5) 
241 (46.5) 
RB status 
deleted  
under- phosphorylated   
hyper-phosphorylated   
 
31 (6.0) 
406 (78.4) 
81 (15.6) 
p53-LI 
< 10 %  
 10 %  
 
407 (78.6) 
111 (21.4) 
Adjuvant therapy 
none  
radiotherapy  
endocrine therapy  alone 
chemotherapy  
 
93 (18.0) 
49 (9.5) 
231 (44.6) 
145 ( 28.0) 
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received chemotherapy (145 cases). In the whole series, the pRb protein expression 
(RB+ or RB-) did not show an significant correlation with prognosis, whereas it 
became a significant predictor of DFS in patients treated with chemotherapy (table 
7). In fact the absence of pRb expression was associated with a better clinical 
outcome in patients treated with chemotherapy.  
 
factor whole series  
of patients (n = 518) 
patients treated with chemotherapy 
(n = 145) 
 No 
patients 
hazard ratio  
(95% CI) 
p-value No 
patients 
hazard ratio  
(95% CI) 
p-value 
pRb expression 
RB- 
RB+   
 
31 
487 
 
1.00 
0.79 (0.43 – 1.47) 
 
 
= 0.469 
 
16 
129 
 
1.00 
5.10 (1.24 –20.86) 
 
 
= 0.023 
ppRb LI 
< 25% 
≥ 25% 
 
406 
81 
 
1.00 
1.95 (1.34 – 2.85) 
 
 
< 0.001 
 
94 
35 
 
1.00 
1.44 (0.84 – 2.45) 
 
 
= 0.178 
Table 7. Univariate analysis of the pRb and ppRb variables for DFS applied to the whole series 
of cases and to patients treated with chemotherapy Abbreviation: 95% CI, 95% confidence interval 
 
 
To evaluate the relationship between the pRb phosphorylation and the patient clinical 
outcome, the ppRb LI variable was analyzed. The ppRb variable was significantly 
associated with DFS in the whole series, whereas it did not significantly in patients 
receiving chemotherapy (Table 7). These results indicated that the lack of pRb and 
not its inactivation by phosphorylation represented a predictive variable of DFS in 
patients who received chemotherapy. 
 
6.2.3. The absence of pRb expression is the only predictive factor of good 
clinical outcome in patients treated with adjuvant chemotherapy 
We have further investigated the relationship between pRb expression and the 
clinical outcome in these two groups of patients (RB- and RB+), considering the 
possibility that the significant predictive effect of pRb found for chemotherapy-
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treated patients might be related to other clinical and histopathologic variables 
associated with the clinical outcome that can confound the results of the statistical 
analysis. We compared the relative predictive value of these variables with that of 
pRb status in a multivariate analysis. The multivariate DFS analysis indicated that 
the absence of pRb expression resulted to be the only significant variable predicting 
the clinical outcome in patients treated with chemotherapy (Table 8). 
 
variable Patients treated with chemotherapy 
 
 hazard ratio  
(95% CI) 
p-value 
pRb expression 
RB- 
RB+ 
 
1.00 
5.56 (1.17-23.71) 
 
 
= 0.030 
p53-LI 
< 10%  
 10%  
 
1.00 
1.49 (0.84 – 1.52) 
 
 
= 0.169 
Tumor size 
pT1  
pT2  
pT3 + pT4  
 
1.00 
0.84 (0.47 – 1.51) 
1.11 (0.50 – 2.42) 
 
 
= 0.574 
= 0.792 
Histological grade  
G1  
G2  
G3  
 
1.00 
1.01 (0.30 – 3.34) 
1.47 (0.41 – 5.28) 
 
 
= 0.980 
= 0.549 
N-status 
N0  
N+  
 
1.00 
2.10 (0.95 – 4.60) 
 
 
= 0.063 
ER status (LI) 
 10%  
< 10%  
 
1.00 
1.00 (0.51 – 1.95) 
 
 
= 0.986 
PR status (LI) 
 10%  
< 10%  
 
1.00 
0.84 (0.46 – 1.52) 
 
 
= 0.569 
HER2-status 
negative  
positive  
 
1.00 
1.75 (0.97 – 3.14) 
 
 
= 0.061 
Ki67-LI 
< 20%  
 20%  
 
1.00 
1.24 (0.97 – 3.14) 
 
 
= 0.570 
Table 8. Multivariate DFS analysis applied to patients treated with chemotherapy 
 
Furthermore because the number of RB- patients treated with chemotherapy was low 
(n=16), we did a DFS analysis comparing the population of patients with RB- cancer 
with a population of patients with RB+ cancer exhibiting the same characteristics 
Results 
94 
 
(high histologic grade (G3), high ki67-LI (>30%), absence of ER) (Table 9). The 
RB- cancers were then matched with RB+ cancers according to these three variables. 
DFS analysis indicated that the pRb expression remained a highly predictive factor 
of a better clinical outcome (Figure 28). 
 
 
variable whole series of cases 
treated with chemotherapy  
(n=145) 
RB- cases  
treated with chemotherapy  
(n=16) 
 n (%) n (%) 
Age 
< 50%  
 50%   
 
63 (43.4) 
82 (56.6) 
 
11 (68.8) 
5 (31.2) 
Histological diagnosis 
ductal carcinomas   
lobular carcinomas  
medullary carcinomas  
mucoid carcinomas  
sarcomatoid carcinomas 
 
132 (91) 
7 (4.8) 
3 (2.1) 
2 (1.4) 
1 (0.7) 
 
16 (100) 
- 
- 
- 
- 
p53-LI 
< 10%  
 10%  
 
96 (66.2) 
49 (33.8) 
 
3 (18.8) 
13 (81.2) 
Tumor size 
pT1  
pT2  
pT3 + pT4  
 
78 (53.8) 
48 (33.1) 
19 (13.1) 
 
7 (43.8) 
6 (37.5) 
3 (18.8) 
Histological grade  
G1  
G2  
G3  
 
15 (10.3) 
37 (25.5) 
93 (64.1) 
 
- 
- 
16 (100) 
N status 
N0  
N+  
 
38 (26.2) 
104 (73.8) 
 
8 (50) 
8 (50) 
ER status (LI) 
 10%  
< 10%  
 
58 (40.0) 
87 (60.0) 
 
16 (100) 
- 
PR status (LI) 
 10%  
< 10%  
 
93 (64.1) 
49 (33.8) 
 
15 (96.8) 
1 (3.2) 
HER2 status 
negative  
positive  
 
70 (48.3) 
75 (51.7) 
 
11 (68.8) 
5 (31.2) 
Ki67-LI 
< 20%  
 20%  
 
44 (30.3) 
101 (69.7) 
 
- 
16 (100) 
Table 9. Multivariate DFS analysis applied to patients treated with chemotherapy 
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Figure 28. Effect of pRb expression on the clinical outcome of patients treated with 
chemotherapy according with the histologic grade, ki67 LI, ER status. DFS curves (Kaplan-Meier 
estimates) for patients treated with chemotherapy with reference to the pRb expression. The16 patients 
with cancer lacking pRb (RB-) showed a better clinical outcome when treated with chemotherapy in 
comparison with 32 patients with RB+ cancer, matched according to histologic grade, Ki67 LI, and 
ER status 
 
6.2.4. 5-FU and MTX treatment hindered cell population growth of RB1-
silenced MCF-7 and HCT-116 cells 
To ascertain whether the better prognosis of pRb-deficient tumors treated with 
adjuvant chemotherapy might be the consequence of a higher sensitivity of pRb-
deficient cells to the drugs used, we studied the response to the 5-FU plus MTX 
drugs in MCF-7 and HCT-116 cells, where the function of pRb was down-regulated 
by RB1-silencing. We evaluated the effect of RB1 silencing on MCF7 (similar data 
were obtained using HCT-116 cells, data not shown) after 48 and 120 hours after the 
RNA interference procedure, both by Real Time RT-PCR, by immunocytochemistry 
and by Western blot analysis (Figure 29).  
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Figure 29. Effect of RB1 interference on RB1 mRNA and pRb protein expression in MCF-7 
cells. A) MCF 7 cells were silenced for RB1 by RNA interference. RB1 mRNA level in cells 
transfected with scrambled sequences (SCR) and in cells silenced for RB1at 48 and120 h after the end 
of the silencing procedure. Note the high reduction of RB1 mRNA in RB1-silenced cells at both the 
times evaluated. B) immunocytochemical pRb staining: Cells transfected with scrambled sequences 
(SCR) showed an intense staining reaction, which was absent in cells silenced for RB1 (RB1i) by 48h 
after the end of the silencing procedure. Bar, 25 µm. C) Western blot analysis of pRb expression in 
control (SCR) and RB1-silenced cells, 48 h after the end of the silencing procedure. Note the strong 
reduction of pRb expression in RB1-silenced cells (RB1i), in comparison with cells transfected with 
scrambled sequences (SCR).The expression of β-actin was used as a control. Histogram shows the 
densitometric values of three independent experiments. Columns, mean; bars, SD. Each value is 
relative to the pRb to β-actin ratio in untreated cells transfected with scrambled sequences (SCR), 
which was set to 100. *, P < 0.05, statistical significance 
 
48h and 120 h after the RNA interference procedure, a strong reduction in RB1 
mRNA expression occurred (Fig. 29 A). Immunocytochemical analysis for pRb 
expression revealed that, as early as 48 hours after the RB1 interference procedure, 
the intensity of the immunostaining was markedly reduced in comparison with 
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control samples (Fig. 29 B) and Western blot analysis confirmed the reduction of 
pRb expression (Fig. 29 C). 
We investigate the long-term effect of 5-FU and MTX treatment on the cell 
population growth in control (SCR) and RB1-silenced MCF-7 and HCT-116 cells 
(Figure 30 A, B). The cell population growth of both MCF-7 and HCT-116 cells 
silenced for RB1 was significantly hindered. On the contrary, regarding the control 
cells, the 5-FU and MTX treatment induced a not significant reduction in the MCF-7 
cell population growth and no reduction at all in the HCT-116 cells. To investigate 
the reason for the reduced growth rate of RB1-silenced MCF-7 and HCT-116 cells 
after drug treatment, we also evaluated the cell death rate in these cells and in control 
cells 24 hours after the end of 5-FU and methotrexate exposure. We found that the 
drug treatment was responsible for a significantly greater mortality in RB1-silenced 
MCF-7 and HCT-116 cells than in control cells (Figure 30 B, D).  
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Fig. 30. Effect of RB1 interference on the growth and mortality rate of MCF-7 and HCT-116 
cells treated with 5-FU and methotrexate. A) and C) the effect of 1-h treatment with 5-FU (20 
µg/mL) and MTX (0.10 µg/mL) on cell population growth of MCF-7 (A) and HCT-116 (C) cells 
either silenced for RB1expression (RB1-) or transfected with scrambled sequences (RB1+). Cell 
number was evaluated 72 h after the end of drug treatment. Drug treatment strongly hindered the 
proliferation of RB1-silenced cells. On the contrary, the drugs only slightly reduced the proliferation 
of the RB1+MCF-7 cells (P = 0.313) and had no effect on RB1+ HCT-116 cells. B) and D) the effect 
of 1-h treatment with 5-FU (20 µg/mL) and methotrexate (0.1 µg/mL) on cell mortality rate. Cell 
number was evaluated 24 h after the end of drug treatment. The percentage of dead cells was greater 
in the drug-treated RB1i MCF-7 and HCT-116 cells than in untreated cells. Drug-treated and 
untreated RB+ cells exhibited the same percentage of dead cells.  *, P < 0.05, statistical significance 
 
6.2.5. 5-FU and MTX treatment caused a cell cycle arrest in control but not in 
RB1-silenced cells 
To obtain information on the cause of the higher sensitivity of RB1-silenced cells to 
5-FU and methotrexate treatment, we evaluated the effect of the drug exposure on 
the cell cycle progression of control and RB1-silenced asynchronously MCF-7 cells, 
by a dual-parameter flow cytometry analysis for DNA content and incorporated 
BrdUrd evaluation (Figure 31).  
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Fig. 31. Effect of 5-FU and methotrexate treatment on cell cycle progression of RB-silenced and 
control MCF-7 cells. Representative dual-parameter flow cytometry analysis of DNA content 
(horizontal) and incorporated BrdUrd (vertical) of asynchronously growing MCF-7 cells either 
silenced for RB1 (RB1-) or transfected with scrambled sequences (RB1+).The cells were labeled with 
BrdUrd for1h, and12h later were either harvested (C) or treated with 5-FU and MTX for1h; these cells 
were processed 12 and 24 h later (T1 and T2, respectively). Each dot plot represents the distribution of 
correlated red (propidium iodide) and green (FITC) fluorescence of 20,000 analyzed cells. Top row, 
MCF-7 cells silenced for RB1. Twelve hours after the end of BrdUrd labeling, both RB1- and RB1+ 
BrdUrd-labeled cells (C) are located in the G0-G1region of the cell cycle. After drug treatment, the 
BrdUrd-labeled cells silenced for RB1seem to move through the S phase (T1) and finally accumulate 
in G2-M (T2), whereas BrdUrd-labeled cells transfected with scrambled sequences seem to be 
arrested in the early S-phase region, without entering the G2-M compartment. Columns, mean 
percentage of cells in theG1, S, and G2-M compartments relative to three independent experiments; 
bars, SD. *, P < 0.05, statistical significance 
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For this purpose, both control and RB1-silenced cells, 72 hours after the end of the 
silencing procedure, were labeled with BrdUrd for 1 hour. Twelve hours later, when 
most of the labeled cells were passed to the G1 phase, the cells were either 
immediately harvested (control cells) or treated with 5-FU and MTX for 1 hour and 
harvested 12 and 24 hours later for dual-parameter flow cytometry analysis. The 
control cells were mainly located in the G0-G1 region. Twelve hours after the 
exposure to 5-FU and MTX, the BrdUrd-labeled RB1-silenced cells seemed to move 
to the S phase and, 24 hours after the end of drug treatment, were accumulated in the 
G2-M region (Fig. 31 A, T1 and T2). On the other hand, at the same time, the 
BrdUrd-labeled, drug treated control cells were prevalently confined to the early S-
phase region and only a limited aliquot was able to reach the G2-M compartment, 
without any accumulation in the G2-M phase compartment (Fig. 31 B, T1 and T2). 
These results indicated that 5-FU and MTX treatment caused an arrest of cell cycle 
progression in control cells but not in RB1-silenced cells. The arrest of cell cycle 
progression in control cells was removed 36 hours after the end of drug treatment. 
 
6.2.6. The p53/p21 pathway was normally activated in RB1-silenced cells treated 
with 5-FU and MTX 
After we investigated whether in RB1-silenced cells the p53-p21 pathway, which is 
involved in genotoxic-induced arrest of cell cycle, was hindered. We evaluated the 
expression of p53 and p21, by Western blot analysis, after 1-hour treatment with 5-
FU plus MTX in control and RB1-silenced MCF-7 cells. We found that in both 
control and RB1-silenced cells, the amount of p53 was greatly increased 6 hours after 
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the drug treatment and progressively decreased thereafter. The expression of p21 
reflected the p53 time course (Figure 32). 
 
 
Figure. 32. Effect of 5-FU and MTX treatment on p53 expression in RB1-silenced MCF-7 cells. 
Representative time course Western blot of p53 and p21 in cells transfected with scrambled sequences 
(RB+) and in cells silenced for RB1 expression (RB-). Cells were either untreated or treated with 5-FU 
and MTX for 1h. An increased amount of p53 was visible 6 h after the treatment and progressively 
decreased thereafter. The expression of p21 reflected the p53 time course. No differences were 
observed in p53 and p21expression between control and silenced cells. Histograms show the 
densitometric values of three independent experiments. Columns, mean; bars, SD. Each value is 
relative to the p53 or p21/h-actin ratio in untreated cells transfected with scrambled sequences, which 
was set to 100 
 
 
6.2.7. RB1-silenced cells accumulated DNA double-strand breaks 
We also investigated whether the higher sensitivity of RB1-silenced cells to drug 
exposure might be the consequence of their reduced capacity for repairing the drug-
induced DNA changes in comparison with control cells. For this purpose, we carried 
out a Western blot analysis with anti-phospho-H2AX antibody to reveal the 
accumulation of DNA double-strand breaks in drug-treated and untreated control and 
RB1-silenced MCF-7 cells (Figure 33). We observed that RB1 silencing caused 
untreated cells markedly to accumulate phosphorylated (γ) H2AX, thus suggesting a 
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failure to repair the endogenously arising double strand breaks promptly enough. The 
level of γ-H2AX seemed not to be increased after drug treatment. Control cells 
showed a very low level of γ-H2AX, which was not modified by drug exposure. 
 
 
 
Figure 33. Effect of 5-FU and MTX treatment on γ-H2AX accumulation in RB1-silenced MCF-7 
cells. Time course Western blot analysis of γ-H2AX expression in control (RB+) and RB1-silenced 
(RB-) cells. Cells were either untreated or treated with 5-FU and MTX for 1h. Note the high 
expression of γ-H2AX in drug-untreated RB1-silenced cells. Drug treatment did not modify the 
expression of γ-H2AX either in control or in RB1-silenced cells 
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6.3. High prevalence of retinoblastoma protein loss in triple-negative breast 
cancers and its association with a good prognosis in patients treated with 
adjuvant chemotherapy 
 
 
6.3.1. Valuation of pRb status and its association of the clinical outcome of 
chemotherapy-treated patients with triple-negative tumors  
In our breast cancer series (518 patients), we identified four immunohistochemical 
profiles according to the expression of hormone receptors and HER2: 
53 tumors as triple-negative cancers, 61 cases pertaining to the ER-, PR- and HER2+ 
subtypes, 284 cases to luminal A (ER+ and/or PR+ and HER2-) and 120 cases to 
luminal B (ER+ and/ or PR+ and HER2+) subtypes (Table 10). The features of 
population enrolled are resumed in table 11. 
 
Immunohistochemical 
subtypes 
Patients 
n 
Triple negative 53 
ER-/PR-/HER2+ 61 
Luminal A 284 
Luminal B 120 
Table 10. Immunohistochemical subtypes identified in the population enrolled 
 
 
 
 
Results 
104 
 
variables  whole series 
518 pz 
triple-negative 
53 (10,2%) 
non 
triple-negative 
465 (89,8%) 
Age  
< 50  
 50   
 
117 (22.6) 
401 (77.4) 
 
19 (35.8) 
34 (64.2) 
 
98 (21.1) 
367 (78.9) 
Histological grade  
G1  
G2  
G3  
 
59 (11.4) 
339 (65.4) 
120 (23.2) 
 
3 (5.7) 
9 (17.0) 
41 (77.4) 
 
101 (21.7) 
183 (39.4) 
181 (38.9) 
N-status (*)  
N0  
N+  
 
275 (53.8) 
237 (46.2) 
 
30 (57.7) 
22 (42.3) 
 
240 (53.2) 
211 (46.8) 
ER-status (LI)  
< 10%  
 10%  
 
123 (23.7) 
395 (76.3) 
 
53 (100.0) 
- 
 
70 (15.1) 
395 (84.9) 
PGR-status (LI)  
< 10%  
 10%  
 
280 (54.1) 
238 (45.9) 
 
53 (100.0) 
- 
 
227 (48.8) 
238 (51.2) 
HER2-status  
negative  
positive  
 
331 (65.0) 
178 (35.0) 
 
53 (100.0) 
- 
 
284 (61.1) 
181 (38.9) 
p53-LI  
< 10 %  
 10 %  
 
407 (78.6) 
111 (21.4) 
 
22 (41.5) 
31 (58.5) 
 
385 (82.8) 
80 (17.2) 
Ki67-LI  
< 20 %  
 20 %  
 
277 (53.5) 
241 (46.5) 
 
9 (17.0) 
44 (83.0) 
 
268 (57.6) 
197 (42.4) 
RB status  
RB deleted  
RB under- phosphorylated   
RB hyper-phosphorylated   
 
31 (6.0) 
406 (78.4) 
81 (15.6) 
 
20 (37.7) 
19 (35.8) 
14 (26.4) 
 
11 (2.4) 
387 (83.2) 
67 (14.4) 
Adjuvant therapy  
none  
radiotherapy  
endocrine therapy alone  
chemotherapy  
 
93 (18.0) 
49 (9.5) 
231 (44.6) 
145 ( 28.0) 
 
7 (13.2) 
7 (13.2) 
15 (28.3) 
24 (45.3) 
 
86 (18.5) 
42 (9.0) 
216 (46.5) 
121 (26.0) 
Table 11. Clinical and histopathological characteristics of triple-negative compared with those 
with other cancer subtypes gathered together in one group (the non triple-negative group). * N 
status was available for 511 cases since, due to patient age, axillary dissection was not carried out in 
seven patients 
 
After we evaluated the clinical outcome (univariate DFS analysis) of the four 
subtypes of tumors, independently of the adjuvant treatment. After a mean follow-up 
time of 109 months, the best prognosis was associated with the luminal A type, 
followed by the triple-negative tumors, whereas a poor clinical outcome was 
associated with both the luminal B and ER2/PR2/HER2+ subtypes.  
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Moreover, adverse events were concentrated, in the triple-negative tumors, in the 
first 40 months after surgery, whereas in other tumor subtypes they were distributed 
throughout the entire follow-up period (Figure 34). 
 
Figure 34. Disease-free survival curves (Kaplan-Meier estimates) according to breast cancer 
subtypes 
 
After we analyzed the clinical outcome of patients according to chemotherapeutic 
treatment. Chemotherapy-treated patients with triple-negative tumors (n=24) 
maintained an optimal prognosis in comparison to those affected by other tumor 
subtypes (Table 12).  
Immunohistochemical 
subtypes 
Patients treated with chemotherapy 
 n DFS rates 
(%) 
Long-rank 
test: χ2 (P) 
Triple negative 24 75.0 13.19 (=0,004) 
ER-/PR-/HER2+ 30 50.0 
Luminal A 45 68.89 
Luminal B 46 39.96 
Table 12. Univariate DFS analysis of different tumor subtypes in patients treated with 
chemotherapy 
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6.3.2. pRb status and the clinical outcome of triple negative tumors treated with 
chemotherapy 
After we evaluated, by immunohistochemical analysis, the pRb status in the different 
tumor subtypes and we distinguished three pRb forms: pRb underphosphorylated, 
pRb hyperphosphorylated, pRb deleted (Table 13). 
 
 Triple 
negative 
ER-/PR-
HER2+ 
Luminal A Luminal B 
pRb loss  
(n=31) 
 
20 (64,5%) 
 
7 (22,6%)  
 
2 (6,5%) 
 
2 (6,5%) 
pRb underphosphorylated 
(n=406) 
 
19 (4,7%) 
 
26 (6,4%) 
 
265(65,3%) 
 
96 (23,6%) 
pRb hyperphosphorylated  
(n= 81) 
 
14 (17,3%) 
 
28 (34,6%) 
 
17 (21,0%) 
 
22 (27,2%) 
Table 13. pRb status in different tumor subtypes  
 
The percentage of tumors without pRb expression was significantly higher in the 
triple-negative subtype (64.5%) than in other tumor subtypes.  After we evaluated the 
clinical outcome of patients with triple-negative tumors treated with chemotherapy 
dividing the cancers in two groups: one characterized by presence of pRb expression 
including the under- and hyper- phosphorylated pRb form, and one with absence of 
pRb expression. All patients with pRb loss were found to be disease free, whereas 
those with normal or hyperphosphorylated-pRb had a significantly poorer prognosis 
(Figure 35). 
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 Total  Number 
Events  
Number 
Censored 
Percent 
Censored  
RB  - 11 0 11 100,00 
RB  + 13 6 7 53,85 
Overall 24 6 18 75,00 
 
 
Figure 35. Disease-free survival curves (Kaplan–Meier estimates) according to pRb status of 
triple-negative patients treated with chemotherapy. RB-: tumors with pRb loss; RB+: pRb 
expressing tumors 
 
 
We have considered the possibility that the highly favorable clinical outcome of 
chemotherapy-treated patients might be related to other anatomo-clinical parameters 
associated with an aggressive phenotype that can confound the results of the 
statistical analysis. For this reason, we analyzed the prognostic relevance of the node 
status, tumor size, histological grade, Ki67- and p53-LI which are well established 
tumor-related factors which might also influence the clinical outcome of the patients 
treated with adjuvant therapy. None of these variables, with the exception or pRb 
status, resulted to be significantly associated with the clinical outcome (Table 14). 
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Variables n DFS rate (%) Long-rank 
test: χ2  
P 
Tumor size 
pT1 
pT2 
pT3 + pT4 
 
9 
11 
4 
 
77,78 
63,64 
100 
 
1,74 
 
= 0,4197 
Histological grade  
G1 + G2  
G3  
 
2 
22 
 
50 
77,27 
 
0,83 
 
= 0,3625 
N-status (*)  
N0  
N+  
 
12 
11 
 
83,33 
64,64 
 
0,90 
 
= 0,3440 
p53-LI  
< 10 %  
 10 %  
 
10 
14 
 
80 
71,43 
 
0,05 
 
= 0,8210 
Ki67-LI  
< 20 %  
 20 %  
 
2 
22 
 
50 
77,27 
 
0,83 
 
= 0,3625 
RB status 
RB- 
RB+ 
 
11 
13 
 
100 
53,85 
 
7,03 
 
= 0,0080 
 
Table 14. Prognostic relevance of tumor size, histological grade, N status, p53 status, 
proliferation rate and pRb status in triple-negative tumors treated with adjuvant chemotherapy 
(n = 24): univariate DFS analysis 
 
 
 
6.3.3. Relevance of pRb status on sensitivity to doxorubicin in MDA-MB-231 
triple-negative derived cells 
In order to demonstrate the relevance of the pRb status in the sensitivity to 
chemotherapeutic agents in TNBCs, we also studied the sensitivity to 5-FU and 
MTX as well as to doxorubicin exposure, in a human triple-negative derived cancer 
cell lines, MDA-MB-231, in which the function of pRb was down-regulated by 
silencing RB1. The effect of RB1-silencing in MDA-MB-231 cells was checked by 
both Real Time-RT PCR and by Western blot analysis (Figure 36).  
48 and 120 h after the RNA interference procedure, a strong reduction of pRb mRNA 
expression occurred in MDA-MB-231 cells (Figure 36 a). Western blot analysis for 
pRb expression confirmed that 48 h after the RB1 silencing procedure, the level of 
pRb was markedly reduced compared to control samples (Figure 36 b).  
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Figure 36. Effect of RB1 interference on RB1mRNA and pRb protein expression on MDA-MB-
231 cells. a) Asynchronously MDA-MB-231 cells were either silenced for RB1expression or 
transfected with control scrambled sequences by RNA interference. The RB1 mRNA level was 
evaluated in cells transfected with control scrambled sequences (SCR) and in cells silenced for RB1 
(RB1i) at 48 and 120 h after the end of the silencing procedure. Note the high reduction of RB1 
mRNA in RB1-silenced cells at both evaluation times. Histograms show the values (mean ± SD) of 
three independent experiments. b) Representative Western blots of pRb expression in MDA-MB-231 
cells, silenced for RB1 expression, 48 h after the end of the silencing procedure, show the strong 
reduction of pRb expression in RB1-silenced cells (RB1i) as compared to cells transfected with 
control scrambled sequences (SCR). The expression of β-actin was used as a control. The histogram 
shows the densitometric values (mean ± SD) of three independent experiments. Each value concerns 
the pRb:β-actin ratio, which was set to 100, in untreated cells transfected with scrambled sequences. 
*p < 0.05 
 
We then investigated the long-term effect of 5-FU plus MTX or doxorubicin 
treatments on the cell population growth in controls and RB1-silenced MDA-MB-
231 cells (Figure 37).  
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Figure 37. Effect of RB1 interference on the growth rate of MDA-MB-231 cells exposed to 
chemotherapeutic agents. The cells were exposed to either 5-FU plus MTX (a) or doxorubicin (b) 
for 2 h daily for 4 consecutive days. The drug treatments started 48 hours after RB1 silencing 
procedure was completed and 24 h after the last treatment the cells were formalin-fixed for the crystal 
violet assay for growth rate evaluation. Values relative to samples not treated with drugs were 
normalized to 100. The histograms show the values (mean ± SD) of three independent experiments. 
statistical significance was: *A= 0,0003 *B< 0.0001  
 
The drug treatments significantly reduced cell population growth both in control and 
RB1-silenced cells, but when pRb was down-regulated the sensitivity to drugs was 
greater. 
 
 
 
 
 
 
 
 
 
 
Discussion 
111 
 
7. DISCUSSION 
 
 
These data show that in breast cancer the response to chemotherapy is conditioned 
both by p53 and pRb status. In fact, when pRb pathway is normally functioning, p53 
is the only independent factor capable to predict the patient clinical outcome after 
adjuvant chemotherapy treatment. pRb alteration characterized by pRb 
hyperphosphorylation reduces the chemosensitivity of cancer cells, independently by 
p53 status, while pRb loss increases the chemosensitivity, always independently by 
p53 status. These data suggest that the assessment of these two genes is necessary to 
have a prognostic indication of response to chemotherapy in breast cancer patients. 
 
Going into detail, clear-cut evidence that the p53 status may influence the response 
to chemotherapeutic agents, and therefore the clinical outcome of breast cancer 
patients, was still lacking. As far as breast cancer is concerned, no consensus was 
established on the predictive role of p53. Several studies, using either 
immunohistochemistry or TP53 gene sequencing for p53 status analysis, supported 
the role of p53 as prognostic marker (Silvestrini et al., 1993; MacGrogan et al., 1995; 
Silvestrini et al., 1996; Thor et al., 1998; Chappuis et al., 1999) and many others 
failed to demonstrated this role (Elledge et al., 1995;  Sjögren et al., 1998; Clahsen et 
al., 1998; Bro¨et et al., 1999; Penault-Llorca et al., 2003). We demonstrated that 
these conflicting data were the results of an alteration of the p53-downstream 
pathway which is frequently disrupted in human cancer cells for RB1 mutation or 
deletion, overexpression of cyclin D1, CDK4, p16INK4a mutation (Knudsen and 
Knudsen, 2008). These changes, by causing either pRb loss or pRb 
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hyperphosphorylation, could either nullify the effect of p53 stabilization after 
chemotherapy treatment or change the sensitivity to chemotherapeutic agents.  
 
7.1. In breast cancer with a normally function of pRb pathway, the p53 status 
was the only independent factor capable to predicting the patient clinical 
outcome after adjuvant chemotherapy treatment 
First, we evaluated the prognostic relevance of p53 in a series of patients according 
to the pRb status, after chemotherapy treatment (5-FU plus MTX). In this series the 
p53 status, considered independently of the pRb status, proved to have a null 
prognostic value.  
Also, in patients with pRb loss and with hyperphosphorylated pRb, the p53 variable 
was not associated with the clinical outcome. As far as the patients with cancer with  
normally functioning pRb pathway (underphosphorylated pRb) was concerned, 
univariate analysis of DFS indicated a significant association of p53 status with 
prognosis, the putatively mutated p53 being associated with a worse clinical 
outcome. In this group, a multivariate analysis of DFS, including the other clinical 
and histopathological variables associated with the clinical outcome such as tumor 
size, histopathological grade, node status, ER-, PR- and Ki67-LI, and HER2, that 
could have confounded the results of the statistical analysis, confirmed that the p53 
status was the only factor significantly associated with the DFS, when pRb was 
normally functioning.  
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7.2. The absence but not functional inactivation of pRb predicted the clinical 
outcome of patients treated with 5-FU and MTX adjuvant therapy 
We evaluated, in a univariate analysis for the DFS, the predictive value of both the 
expression of pRb and the degree of its phosphorylation in the whole series of 
patients and in the patients who received standard chemotherapy regimen (5-FU plus 
MTX). In fact, there is evidence that from the functional point of view, 
hyperphosphorylation abolishes the tumor suppressor activity of pRb (Sherr and 
McCormick, 2002). Thus, regarding the biological behavior of cancer cells, both the 
lack of pRb expression and pRb hyperphosphorylation might have similar effects. 
We subdivided the tumors into two groups: one characterized by the presence of pRb 
expression, which included the underphosphorylated and hyperphosphorylated pRb 
form (RB+), one with a deleted pRb status (RB-). 
Regarding the relationship between pRb expression and patient clinical outcome, we 
found that this pRb variable (RB- or RB+) was not a significant prognostic parameter 
in the whole series of patients. However, among the patients who received 
chemotherapy, those whose cancers lacked pRb (RB-) had a better prognosis than 
those expressing the tumor suppressor protein. 
About the relationship between the level of pRb phosphorylation and prognosis, we 
found that the level of pRb phosphorylation not correlated with the clinical outcome 
in patients who received chemotherapy. Therefore, only the loss of pRb, but not its 
inactivation for hyperphosphorylation, was a predictive factor of the clinical outcome 
of breast cancer patients, when treated with chemotherapy. 
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7.3. Lack of pRb expression was the only independent factor predicting a good 
clinical outcome in patients treated with adjuvant chemotherapy 
We further investigated this relationship between pRb expression and the clinical 
outcome in patients treated with chemotherapy, considering the possibility that the 
significant predictive effect of pRb found might have been related to other clinical 
and histopathological variables associated with the clinical outcome, such as node 
status, tumor size, histologic grade, ER-, PR-, Ki67-, and p53- LI and HER2 status, 
confounding these results. So we carried out a multivariate analysis for DFS and we 
found that the pRb expression resulted to be the only significant predictive factor 
associated with the prognosis in patients treated with chemotherapy: the group of 
patients with RB- cancers having a better clinical outcome than those with RB+ 
cancer. Furthermore, because the number of breast cancers lacking pRb was small (n 
= 16), to validate the significant association between pRb expression and prognosis 
the 16 RB- tumors were matched with 32 RB+ tumors according those variables that 
characterized all the RB- tumors (high histologic grade, high proliferation rate, and 
absence of ER). Also, in this data set, patients with tumors lacking pRb expression 
had a significantly better clinical outcome than patients with RB+ tumors. Therefore, 
even if the number of breast cancers lacking pRb expression is only a small fraction 
of total breast cancers, altogether these data indicated the only independent factor 
predicting a good clinical outcome in patients treated with adjuvant chemotherapy 
was the loss of pRb. 
 
In order to demonstrate that a normally functioning pRb pathway was necessary to 
allow wild-type p53 to induce a cytostatic activity after the exposure to 
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chemotherapeutic agents, we analyzed the response to chemotherapeutic drugs, used 
in breast cancer therapy, in human cancer cell lines with either wild-type or 
abrogated p53 function (to inhibit p53 activity we have both interfered TP53 gene 
and used an inactive truncated-dominant negative form of murine p53 (p53DD)) 
where the function of pRb was down-regulated either by abolishing the expression of 
pRb by RB1-silencing, or by inducing pRb hyperphosphorylation by p16INK4a-
silencing. Therefore, we first evaluated the effects of the loss of pRb on the cell 
proliferation rate of a p53-deficient and p53-proficient cell lines treated either with 5-
FU plus MTX or doxorubicin. As for the effect of the loss of pRb on the sensitivity 
of p53-deficient and p53-proficient cells to drug exposure, we found that in cell lines 
where p53 was inactivated, the inhibitory effect of drugs on the cell population 
growth rate was greatly reduced as compared to cells harboring wild-type p53. RB1 
silencing restored the high sensitivity to drugs in cells with inactivated p53 and the 
cell population growth rate being the same as that of cells with wild-type p53.  
There is evidence that the loss of pRb actually increases cell sensitivity to both 
DNA-damaging agents and drugs targeting the thymidylate biosynthesis pathway 
(Knudsen and Knudsen, 2008) The present results demonstrated that the high 
sensitivity of pRb-deficient breast cancer cells, both to drugs targeting the 
thymidylate biosynthesis pathway and to doxorubicin, were not influenced by p53 
status and explain why tumours with mutated p53 could strongly benefit from 
chemotherapy if they were also characterized by the loss of pRb. 
As for the effect of pRb pathway inactivation, our results showed that pRb 
hyperphosphorylation, caused by p16INK4a silencing, reduced the sensitivity to 
doxorubicin in p53-proficient HepG2 cells. Since drug treatment of p53-proficient 
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HepG2 cells caused the disappearance of the phosphorylated form of pRb in controls 
but not in p16INK4a-silenced cells, our results demonstrate that p53 stabilization had 
a lower cytostatic effect in p16INK4a-silenced cells, which was very likely due to the 
persistence of phosphorylated pRb within cancer cells. These results were consistent 
with the established mechanism of cell cycle progression blockage induced by the 
activation of the p53-p21 pathway leading to the inhibition of pRb phosphorylation: 
pRb hyperphosphorylation hinders p53-mediated cell cycle arrest (Knudsen and 
Knudsen, 2008). They also explain well the observations that breast cancer patients 
with hyperphosphorylated pRb and treated with adjuvant chemotherapy were 
characterized by a poor prognosis that was independent of the p53 status. Our results 
indicated that in breast cancers, as it has also been previously reported to occur in 
non-small cell lung cancer (Burke et al., 2005), the complexity of the cell cycle 
protein interaction warrants caution in interpreting survival results when specific 
protein abnormalities are taken in isolation. 
 
7.4. The greater sensitivity of pRb deficient cells to 5-FU plus MTX exposure 
was due to the absence of a DNA damage checkpoint and DNA repair 
mechanisms 
To ascertain the mechanism at the basis of the enhanced sensitivity of pRb negative 
tumors to antimetabolites action, we analyzed the effect of 5-FU and MTX treatment 
on cell cycle progression in MCF-7 cells.  
Analysis of the cytofluorimetric results indicated that 1-hour drug treatment caused 
an arrest of cell cycle progression in control cells but not in RB1-silenced MCF-7 
cell. These data were consistent with the available evidence indicating that several 
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DNA damage inducers used in human tumor chemotherapy inhibit G1- and S-phase 
progression in pRb-proficient but not in pRb-deficient cells (Knudsen KE et al., 
2000; Angus SP et al., 2002). Specifically, it has been shown that pRb-proficient 
cells exposed to 5-FU failed to accumulate in any phase of the cell cycle, indicating 
that the drug was responsible for the arrest in all phases of the cell cycle (Mayhew et 
al., 2004). We also investigated whether in RB1-silenced cells the p53/p21 pathway, 
which is usually involved in the genotoxic-induced arrest of cell cycle progression 
(Sherr CJ and McCormick F, 2002) was hindered. We evaluated the expression of 
p53 after 1-hour treatment with 5-FU and MTX in control and RB1-silenced MCF-7 
cells and we found that in both control and RB1-silenced cells, the amount of p53 
was greatly increased after the drug treatment, indicating a functional p53 pathway.  
We also investigated whether the higher sensitivity of pRb-deficient cells to drug 
exposure could have been the consequence of their reduced capacity for repairing the 
drug-induced DNA changes. We demonstrated that RB1-silenced cells exhibited 
elevated levels of γ-H2AX, indicative of defects in the DNA repair machinery, 
whereas the control cells did not shown accumulation of double strand breaks, thus 
indicating a normal DNA repairing activity. In other words, pRb-proficient cells may 
be more resistant to anti-metabolite exposure than pRb-deficient cells because they 
have the time for repairing the 5-FU-induced damage by possessing functioning cell 
cycle checkpoint and DNA repair mechanisms. This repair would be impossible for 
cells lacking pRb in which the DNA damaging agents do not induce arrest of cell 
cycle progression and DNA repair mechanisms are hindered.  
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7.5. High prevalence of retinoblastoma protein loss in triple-negative breast 
cancers was responsible for a good prognosis in patients treated with adjuvant 
chemotherapy  
The triple negative breast cancers (TNBCs) are a particular subtype of breast 
carcinomas. They are very aggressive and due to absence of hormone receptors and 
HER2, they are treated only with adjuvant chemotherapy. 
It is worth noting that they exhibit higher rates of objective response to 
chemotherapy then other tumor types. This suggests that the biological features 
present more frequently in this subtype are responsible for their increased sensitivity 
to chemotherapy.  
Since we demonstrated that breast cancers lacking pRb expression were more 
sensitive to adjuvant chemotherapy, we investigated whether the high sensitivity to 
chemotherapy of TNBCs could be due to the loss of pRb. 
We carried out an immunohistochemical analysis on a large consecutive series of 
primary breast cancer to identify the breast cancer subtypes. In our breast cancer 
series, we identified 53 tumors as triple negative cancers, corresponding to 10.2% of 
the 518 cases taken into account. This value was within the range (10%–17%) 
reported for the frequency of triple-negative cancers among all breast cancers (Reis-
Filho and Tutt, 2008). Then we evaluated the clinical outcome of the four subtypes 
of tumors independently of the adjuvant treatment received. After a mean follow-up 
time of 109 months, the best prognosis was associated with the luminal A type, 
followed by the triple-negative tumors. Therefore, in our series, triple negative 
tumors did not appear to be characterized by a more aggressive clinical behavior 
compared with other types of breast cancer. According to the previous results (Dent 
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et al., 2007), we found that in patients with triple-negative tumors, adverse events 
were concentrated in the first 40 months after surgery, whereas in other tumor 
subtypes they were distributed throughout the entire follow-up period. We also 
analyzed the clinical outcome of patients according to their adjuvant therapy 
treatment. Chemotherapy-treated patients with triple-negative tumors were 
characterized by a very good prognosis in comparison to those affected by other 
tumor subtypes. 
We evaluated the pRb status on the four breast cancer subtypes and we found that 
64.5% of pRb-deficient tumors were triple-negative cases and that 37.7% of triple-
negative tumors were pRb deficient compared with 2.3% of other cancer types. 
Regarding pRb inactivation by hyperphosphorylation, the percentage of TNBCs with 
hyperphosphorylated pRb was not significantly different to that of other cancer 
subtypes, thus indicating that pRb loss, but not pRb functional inactivation by 
hyperphosphorylation, represented a frequent biological characteristic of triple-
negative tumors. We evaluated the clinical outcome of patients with triple-negative 
tumors treated with chemotherapy according to the presence or absence of pRb 
expression. We subdivided the tumors into two groups: one characterized by the 
presence of pRb expression, which included the underphosphorylated and 
hyperphosphorylated pRb form (RB+), one with a deleted pRb status (RB-). 
We demonstrated that all patients with pRb loss were found to be disease free, 
whereas those with normal or hyperphosphorylated-pRb had a significantly poorer 
prognosis, indicating that the lack of pRb expression represented a strong predictive 
parameter of DFS in TNBC patients who received chemotherapy.  
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We considered the possibility that the highly favorable clinical outcome of 
chemotherapy-treated patients could be related to other anatomo-clinical parameters 
associated with an aggressive phenotype, confusing the results of the statistical 
analysis. For this reason, we analyzed the prognostic relevance of the node status, 
tumor size, histological grade, Ki67- and p53-LI which were well established tumor-
related factors which could influence the clinical outcome of the patients treated with 
adjuvant therapy. We confirmed that none of these variables resulted to be associated 
with the clinical outcome, with the exception of pRb status which was the only 
predictive factor significantly associated with the clinical outcome.  
We also confirmed the effect of loss of pRb on the sensitivity to drug exposure in a 
triple-negative derived cell lines, the MDA-MB-231.  
In conclusion, triple negative cancers seemed to harbor a biological feature that, 
when present, made them highly sensitive to chemotherapy. In the absence of this 
specific feature, the highly aggressive phenotype of these cancers would determine 
the poor clinical outcome for patients. In the present study we found that the lack of 
pRb expression was more frequent in TNBCs than in other cancer subtypes, and 
patients with triple-negative tumors lacking pRb had a very favorable clinical 
outcome if treated with adjuvant chemotherapy. Therefore, we suggested that the loss 
of pRb expression was this biological feature. 
 
In conclusion, taken together, these data indicate that p53 and pRb are key elements 
for the determination and prediction of response to chemotherapy, in particular in 
breast cancer, just because their function is to control the cell cycle and to respond to 
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any damages, including those induced by chemotherapy drugs (Figure 38) 
Alterations of p53-pRb pathway may influence the chemosensitivity. 
We observed that in breast cancer with a normally functioning pRb pathway, p53 
was the only independent factor capable of predicting the patient clinical outcome 
after adjuvant chemotherapy treatment. Regarding the pRb alterations, we found that 
the pRb functional inactivation (pRb hyperphosphorylated) reduced the 
chemosensitivity, independently by p53 status; whereas the cancers with pRb loss 
increased the sensitivity to chemotherapy, always independently by p53 status, and 
the patients had a better prognosis (Figure 39). Therefore, the pRb loss was the only 
predictive factors of a good clinical outcome for patients treated with adjuvant 
chemotherapy, especially in a particular subtype of breast cancers, the triple-negative 
tumors, characterized by a large amount of pRb-deleted tissues. 
Therefore, the systemic chemotherapy should be considered to represent the first 
choice adjuvant treatment for patients with pRb negative cancers. 
These studies allow us to suggest the introduction into clinical practice, beyond the 
already known assessment of p53, also the concomitant evaluation of the pRb 
expression because together they represent two important, related and strong 
prognostic and predictive parameters of clinical outcome of patients with breast 
cancers and treated with chemotherapy. 
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Figure 38. Schematic representation of the p53-pRb pathway activated by chemotherapeutic 
treatments 
 
 
 
 
 
Figure 39. Schematic representation of prognostic relevance of pRb and p53 status to predict 
the clinical outcome of breast cancer patients treated with chemotherapy  
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cells to chemotherapeutic agents is conditioned by the status of the 
retinoblastoma protein. J Pathol. 2009 Nov; 219(3):373-82. 
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Montanaro and M Derenzini. High prevalence of retinoblastoma protein loss 
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